Elucidation	O
of	O
the	O
Interaction	O
Mechanism	O
with	O
Liposomes	O
of	O
gH625	O
-	O
Peptide	O
Functionalized	O
Dendrimers	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
SG	O
MW	O
MG	O
.	O

Performed	O
the	O
experiments	O
:	O
AF	O
RT	O
TC	O
.	O

Analyzed	O
the	O
data	O
:	O
SG	O
.	O

Wrote	O
the	O
paper	O
:	O
SG	O
MW	O
MG	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
SG	O
.	O

We	O
have	O
demonstrated	O
that	O
amide	O
-	O
based	O
dendrimers	O
functionalized	O
with	O
the	O
membrane	O
-	O
interacting	O
peptide	O
gH625	O
derived	O
from	O
the	O
herpes	B-OG
simplex	I-OG
virus	I-OG
type	I-OG
1	I-OG
(	O
HSV	B-OG
-	I-OG
1	I-OG
)	O
envelope	B-GP
glycoprotein	I-GP
H	I-GP
enter	O
cells	O
mainly	O
through	O
a	O
non	O
-	O
active	O
translocation	O
mechanism	O
.	O

Herein	O
,	O
we	O
investigate	O
the	O
interaction	O
between	O
the	O
peptide	O
-	O
functionalized	O
dendrimer	O
and	O
liposomes	O
composed	O
of	O
PC	O
/	O
Chol	O
using	O
fluorescence	O
spectroscopy	O
,	O
isothermal	O
titration	O
calorimetry	O
,	O
and	O
surface	O
plasmon	O
resonance	O
to	O
get	O
insights	O
into	O
the	O
mechanism	O
of	O
internalization	O
.	O

The	O
affinity	O
for	O
the	O
membrane	O
bilayer	O
is	O
very	O
high	O
and	O
the	O
interaction	O
between	O
the	O
peptide	O
-	O
dendrimer	O
and	O
liposomes	O
took	O
place	O
without	O
evidence	O
of	O
pore	O
formation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
presented	O
peptidodendrimeric	O
scaffold	O
may	O
be	O
a	O
promising	O
material	O
for	O
efficient	O
drug	O
delivery	O
.	O

Introduction	O

The	O
cellular	O
membrane	O
plays	O
an	O
essential	O
role	O
in	O
controlling	O
the	O
transport	O
of	O
external	O
molecules	O
into	O
the	O
cell	O
interior	O
.	O

It	O
acts	O
as	O
a	O
selective	O
barrier	O
that	O
only	O
allows	O
the	O
passage	O
of	O
selected	O
molecules	O
.	O

Non	O
-	O
specific	O
and	O
non	O
-	O
disruptive	O
penetration	O
across	O
the	O
membrane	O
without	O
protein	O
mediation	O
is	O
typically	O
achievable	O
only	O
by	O
small	O
molecules	O
,	O
while	O
larger	O
ones	O
generally	O
induce	O
significant	O
disruption	O
of	O
the	O
lipid	O
bilayer	O
structure	O
[	O
1	O
].	O

Thus	O
,	O
there	O
is	O
considerable	O
interest	O
to	O
pave	O
the	O
way	O
to	O
strategies	O
able	O
to	O
translocate	O
synthetic	O
molecules	O
into	O
and	O
through	O
the	O
membrane	O
for	O
drug	O
delivery	O
,	O
biosensing	O
,	O
and	O
other	O
biomedical	O
applications	O
,	O
without	O
permanently	O
disrupting	O
the	O
membrane	O
and	O
the	O
risk	O
of	O
inducing	O
cell	O
death	O
[	O
2	O
].	O

The	O
success	O
of	O
novel	O
strategies	O
for	O
health	O
care	O
therapies	O
relies	O
on	O
the	O
development	O
of	O
delivery	O
vehicles	O
capable	O
of	O
improving	O
the	O
therapeutic	O
index	O
of	O
biologically	O
active	O
molecules	O
as	O
well	O
as	O
diagnosing	O
at	O
the	O
disease	O
site	O
of	O
interest	O
.	O

At	O
the	O
present	O
,	O
most	O
active	O
compounds	O
are	O
not	O
deemed	O
therapeutically	O
effective	O
due	O
to	O
their	O
inability	O
to	O
reach	O
the	O
target	O
tissue	O
.	O

A	O
variety	O
of	O
drug	O
delivery	O
carriers	O
including	O
polymer	O
microcapsules	O
,	O
liposomes	O
,	O
polymer	O
conjugates	O
,	O
and	O
nanoparticles	O
are	O
in	O
pre	O
-	O
clinical	O
and	O
clinical	O
development	O
to	O
improve	O
many	O
drug	O
bioavailability	O
,	O
especially	O
for	O
cancer	B-DS
treatment	O
[	O
3	O
],	O
[	O
4	O
].	O

Most	O
drug	O
carriers	O
lack	O
the	O
potential	O
for	O
orthogonal	O
multi	O
-	O
functionalization	O
,	O
a	O
prerequisite	O
for	O
theranostics	O
and	O
are	O
often	O
not	O
well	O
-	O
defined	O
compounds	O
but	O
polydisperse	O
mixtures	O
,	O
rendering	O
the	O
analysis	O
of	O
structure	O
-	O
property	O
relationships	O
challenging	O
.	O

These	O
drawbacks	O
limit	O
their	O
potential	O
use	O
in	O
theranostics	O
.	O

One	O
class	O
of	O
biomaterials	O
that	O
can	O
serve	O
as	O
drug	O
carrier	O
or	O
,	O
more	O
generally	O
as	O
a	O
platform	O
for	O
theranostics	O
,	O
and	O
that	O
has	O
the	O
potential	O
to	O
overcome	O
these	O
limitations	O
is	O
dendrimers	O
.	O

Dendrimers	O
are	O
well	O
-	O
defined	O
synthetic	O
hyperbranched	O
macromolecules	O
which	O
possess	O
a	O
high	O
number	O
of	O
active	O
termini	O
that	O
defines	O
their	O
properties	O
and	O
functions	O
[	O
5	O
].	O

As	O
a	O
result	O
of	O
perfect	O
branching	O
,	O
dendrimers	O
have	O
the	O
highest	O
number	O
of	O
terminal	O
functionalities	O
of	O
any	O
polymeric	O
material	O
at	O
a	O
given	O
molecular	O
weight	O
and	O
are	O
monodisperse	O
.	O

Comparing	O
the	O
features	O
of	O
dendrimers	O
with	O
those	O
of	O
linear	O
polymers	O
,	O
it	O
was	O
shown	O
that	O
the	O
dendrimer	O
architecture	O
presents	O
several	O
advantages	O
for	O
drug	O
delivery	O
[	O
6	O
],	O
[	O
7	O
]:	O
(	O
i	O
)	O
low	O
polydispersity	O
allowing	O
for	O
reproducible	O
pharmacokinetic	O
behavior	O
;	O
ii	O
)	O
globular	O
shape	O
of	O
higher	O
generation	O
dendrimers	O
affecting	O
their	O
biological	O
and	O
rheological	O
properties	O
;	O
and	O
iii	O
)	O
controlled	O
multivalency	O
which	O
can	O
be	O
used	O
to	O
attach	O
several	O
molecules	O
,	O
e	O
.	O
g	O
.	O
drugs	O
,	O
imaging	O
agents	O
,	O
cell	O
-	O
penetrating	O
peptides	O
,	O
targeting	O
groups	O
,	O
and	O
/	O
or	O
solubilizing	O
moieties	O
.	O

The	O
possibility	O
to	O
introduce	O
several	O
functionalities	O
into	O
the	O
dendrimer	O
structures	O
has	O
opened	O
the	O
door	O
for	O
their	O
applications	O
in	O
theranostics	O
[	O
8	O
].	O

Over	O
the	O
past	O
decade	O
,	O
the	O
relationships	O
between	O
dendrimer	O
architecture	O
,	O
biocompatibility	O
,	O
circulation	O
time	O
,	O
and	O
release	O
kinetics	O
have	O
been	O
partially	O
elucidated	O
allowing	O
the	O
development	O
of	O
general	O
principles	O
for	O
the	O
design	O
of	O
dendrimers	O
as	O
“	O
ideal	O
”	O
drug	O
delivery	O
carriers	O
.	O

These	O
include	O
PEGylation	O
to	O
increase	O
water	O
solubility	O
,	O
permeability	O
,	O
stability	O
and	O
dendrimer	O
size	O
(	O
leading	O
to	O
tunable	O
retention	O
and	O
biodistribution	O
characteristics	O
),	O
the	O
internalization	O
of	O
therapeutic	O
agents	O
into	O
the	O
void	O
space	O
between	O
the	O
branches	O
or	O
the	O
covalent	O
attachment	O
of	O
them	O
to	O
surface	O
groups	O
,	O
and	O
the	O
addition	O
of	O
targeting	O
moieties	O
bound	O
to	O
the	O
dendrimer	O
surface	O
can	O
be	O
used	O
to	O
preferentially	O
treat	O
disease	O
cells	O
with	O
specific	O
over	O
-	O
expressed	O
receptor	O
targets	O
.	O

Dendrimers	O
usually	O
cross	O
cell	O
barriers	O
by	O
endocytosis	O
[	O
9	O
],	O
[	O
10	O
],	O
thus	O
they	O
are	O
entrapped	O
in	O
endososomes	O
and	O
only	O
a	O
small	O
amount	O
of	O
the	O
active	O
drug	O
is	O
able	O
to	O
reach	O
the	O
intracellular	O
target	O
.	O

We	O
recently	O
reported	O
that	O
virally	O
derived	O
peptides	O
could	O
significantly	O
help	O
in	O
solving	O
this	O
problem	O
as	O
many	O
viruses	B-OG
have	O
evolved	O
rather	O
efficient	O
systems	O
for	O
endosomal	O
release	O
.	O

Viruses	B-OG
can	O
enter	O
cells	O
either	O
through	O
an	O
endosomal	O
pathway	O
or	O
via	O
direct	O
fusion	O
of	O
the	O
plasma	O
membrane	O
through	O
the	O
activity	O
of	O
membranotropic	O
peptides	O
[	O
11	O
],	O
[	O
12	O
].	O

Great	O
attention	O
has	O
been	O
devoted	O
to	O
the	O
study	O
of	O
hydrophobic	O
peptides	O
that	O
efficiently	O
traverse	O
biological	O
membranes	O
,	O
promoting	O
lipid	O
-	O
membrane	O
reorganizing	O
processes	O
,	O
such	O
as	O
fusion	O
or	O
pore	O
formation	O
,	O
and	O
involving	O
temporary	O
membrane	O
destabilization	O
and	O
subsequent	O
reorganization	O
[	O
13	O
],	O
[	O
14	O
],	O
[	O
15	O
],	O
[	O
16	O
],	O
[	O
17	O
],	O
[	O
18	O
],	O
[	O
19	O
],	O
[	O
20	O
].	O

These	O
peptides	O
are	O
significantly	O
different	O
from	O
the	O
well	O
-	O
known	O
cell	O
penetrating	O
cationic	O
peptides	O
such	O
as	O
TAT	O
,	O
which	O
do	O
not	O
translocate	O
spontaneously	O
across	O
bilayers	O
but	O
rather	O
are	O
taken	O
up	O
by	O
cells	O
via	O
endocytosis	O
[	O
21	O
].	O

According	O
to	O
our	O
previously	O
reported	O
data	O
[	O
22	O
],	O
[	O
23	O
],	O
coupling	O
of	O
a	O
poly	O
(	O
amide	O
)-	O
based	O
dendrimer	O
[	O
24	O
],	O
[	O
25	O
]	O
to	O
viral	O
peptide	O
gH625	O
enabled	O
the	O
non	O
-	O
specifically	O
crossing	O
of	O
the	O
membrane	O
bilayer	O
through	O
an	O
energy	O
-	O
independent	O
process	O
,	O
without	O
showing	O
evidence	O
of	O
endocytosis	O
,	O
poration	O
,	O
or	O
cytotoxicity	O
.	O

Translocation	O
mediated	O
by	O
gH625	O
may	O
be	O
very	O
useful	O
in	O
the	O
delivery	O
of	O
drugs	O
;	O
the	O
mechanism	O
of	O
spontaneous	O
translocation	O
is	O
not	O
yet	O
well	O
understood	O
.	O

The	O
translocation	O
of	O
gH625	O
dendrimers	O
through	O
lipid	O
bilayers	O
could	O
provoke	O
changes	O
in	O
the	O
bilayer	O
which	O
need	O
to	O
be	O
taken	O
into	O
account	O
in	O
the	O
design	O
of	O
a	O
drug	O
controlled	O
release	O
delivery	O
system	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
our	O
HSV	B-OG
-	I-OG
1	I-OG
derived	O
peptide	O
-	O
dendrimer	O
to	O
mediate	O
the	O
cell	O
membrane	O
crossing	O
,	O
it	O
is	O
necessary	O
to	O
understand	O
its	O
interactions	O
with	O
lipid	O
bilayers	O
[	O
26	O
].	O

Liposomes	O
are	O
excellent	O
model	O
systems	O
for	O
biological	O
experiments	O
because	O
of	O
their	O
simple	O
and	O
membrane	O
-	O
like	O
composition	O
,	O
easy	O
preparation	O
,	O
biodegradability	O
,	O
biocompatibility	O
and	O
acceptable	O
stability	O
over	O
time	O
.	O

By	O
examining	O
the	O
interactions	O
between	O
liposomes	O
and	O
dendrimers	O
,	O
conclusions	O
can	O
be	O
drawn	O
about	O
biological	O
processes	O
such	O
as	O
membrane	O
fusion	O
and	O
translocation	O
and	O
ultimately	O
transport	O
pathways	O
for	O
drug	O
delivery	O
.	O

In	O
the	O
literature	O
,	O
several	O
modes	O
of	O
interactions	O
between	O
dendrimers	O
and	O
liposomes	O
are	O
described	O
[	O
27	O
],	O
[	O
28	O
],	O
[	O
29	O
],	O
[	O
30	O
],	O
[	O
31	O
],	O
[	O
32	O
],	O
[	O
33	O
],	O
[	O
34	O
],	O
[	O
35	O
],	O
[	O
36	O
],	O
[	O
37	O
],	O
[	O
38	O
].	O

Dendrimers	O
can	O
either	O
pass	O
through	O
the	O
lipid	O
bilayer	O
or	O
dendrimer	O
-	O
lipid	O
micelles	O
are	O
created	O
[	O
39	O
].	O

Some	O
dendrimers	O
can	O
interact	O
with	O
lipids	O
by	O
hydrophobic	O
interactions	O
between	O
lipid	O
acyl	O
chains	O
and	O
the	O
hydrophobic	O
dendrimer	O
interior	O
[	O
40	O
],	O
[	O
41	O
].	O

It	O
was	O
shown	O
that	O
the	O
strength	O
of	O
the	O
interaction	O
mainly	O
depends	O
on	O
the	O
size	O
and	O
charge	O
of	O
the	O
molecule	O
[	O
42	O
],	O
[	O
43	O
],	O
[	O
44	O
]	O
and	O
the	O
phase	O
of	O
lipids	O
[	O
45	O
].	O

This	O
contribution	O
describes	O
the	O
effect	O
of	O
the	O
gH625	O
dendrimer	O
on	O
lipid	O
bilayers	O
composed	O
of	O
cholesterol	O
(	O
Chol	O
)	O
and	O
neutral	O
phospholipids	O
such	O
as	O
phosphatidylcholine	O
(	O
PC	O
).	O

Surface	O
plasmon	O
resonance	O
(	O
SPR	O
),	O
fluorescence	O
spectroscopy	O
,	O
and	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
were	O
used	O
to	O
elucidate	O
the	O
dendrimer	O
/	O
membrane	O
interactions	O
in	O
order	O
to	O
push	O
further	O
the	O
design	O
of	O
new	O
drug	O
delivery	O
systems	O
that	O
consist	O
of	O
dendrimers	O
incorporating	O
bioactive	O
molecules	O
.	O

These	O
studies	O
are	O
of	O
interest	O
in	O
understanding	O
the	O
interaction	O
of	O
gH625	O
-	O
dendrimer	O
with	O
native	O
cell	O
membranes	O
,	O
and	O
complement	O
previous	O
studies	O
showing	O
that	O
the	O
gH625	O
-	O
dendrimer	O
is	O
able	O
to	O
pass	O
through	O
and	O
does	O
not	O
disrupt	O
the	O
biological	O
membrane	O
.	O

Materials	O
and	O
Methods	O

Materials	O

Fmoc	O
-	O
protected	O
amino	O
acids	O
,	O
coupling	O
reagents	O
,	O
and	O
Rink	O
-	O
amide	O
p	O
-	O
methylbenzhydrylamine	O
(	O
MBHA	O
)	O
resin	O
were	O
purchased	O
from	O
Calbiochem	O
-	O
Novabiochem	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
).	O

Fmoc	O
-	O
l	O
-	O
propargylglycine	O
(	O
Fmoc	O
-	O
PrA	O
-	O
OH	O
)	O
was	O
purchased	O
from	O
NeoSystem	O
(	O
Tysons	O
Corner	O
,	O
VA	O
,	O
USA	O
).	O

The	O
phospholipid	O
phosphatidylcholine	O
(	O
PC	O
),	O
1	O
-	O
hexadecanoyl	O
-	O
2	O
-(	O
6	O
,	O
7	O
-	O
dibromooctadecanoyl	O
)-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphocholine	O
(	O
6	O
,	O
7	O
Br	O
-	O
PC	O
),	O
1	O
-	O
hexadecanoyl	O
-	O
2	O
-(	O
9	O
,	O
10	O
-	O
dibromooctadecanoyl	O
)-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphocholine	O
(	O
9	O
,	O
10	O
Br	O
-	O
PC	O
),	O
1	O
-	O
hexadecanoyl	O
-	O
2	O
-(	O
11	O
,	O
12	O
-	O
dibromooctadecanoyl	O
)-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphocholine	O
(	O
11	O
,	O
12	O
Br	O
-	O
PC	O
)	O
were	O
purchased	O
from	O
Avanti	O
Polar	O
Lipids	O
(	O
Birmingham	O
,	O
AL	O
,	O
USA	O
).	O

Cholesterol	O
,	O
Triton	O
-	O
X100	O
and	O
3	O
-	O
propyl	O
-	O
2	O
-(	O
5	O
-(	O
3	O
-	O
propyl	O
)-	O
2	O
(	O
3H	O
)-	O
benzothiazolidene	O
-	O
1	O
,	O
3	O
-	O
pentadienyl	O
),	O
iodide	O
(	O
diS	O
-	O
C3	O
-	O
5	O
)	O
were	O
obtained	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

All	O
other	O
chemicals	O
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
),	O
Alfa	O
Aesar	O
(	O
Ward	O
Hill	O
,	O
MA	O
,	O
USA	O
),	O
or	O
TCI	O
International	O
(	O
Portland	O
,	O
Oregon	O
,	O
USA	O
).	O

Ultrafiltration	O
membranes	O
were	O
purchased	O
from	O
Millipore	O
.	O

Analytical	O
and	O
semi	O
-	O
prep	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
performed	O
on	O
a	O
Shimadzu	O
LC8	O
pump	O
setup	O
using	O
Phenomenex	O
C4	O
(	O
4	O
.	O
6	O
×	O
150	O
mm	O
-	O
5	O
µm	O
,	O
10	O
×	O
250	O
mm	O
-	O
10	O
µm	O
)	O
columns	O
.	O

gH625	O
-	O
dendrimer	O
preparation	O

The	O
dendrimer	O
and	O
the	O
peptide	O
have	O
been	O
synthesized	O
as	O
previously	O
reported	O
[	O
22	O
],	O
[	O
23	O
].	O

To	O
obtain	O
the	O
peptidodendrimer	O
,	O
a	O
1	O
∶	O
1	O
methanol	O
/	O
water	O
solution	O
of	O
peptide	O
gH625	O
–	O
PrA	O
(	O
660	O
µl	O
,	O
36	O
equiv	O
),	O
an	O
aqueous	O
solution	O
of	O
CuSO4	O
·	O
5H2O	O
(	O
10	O
µl	O
,	O
1	O
.	O
46	O
mM	O
,	O
1	O
equiv	O
),	O
and	O
an	O
aqueous	O
solution	O
of	O
sodium	O
ascorbate	O
(	O
50	O
µl	O
,	O
1	O
.	O
17	O
mM	O
,	O
4	O
equiv	O
)	O
were	O
added	O
to	O
the	O
dendrimer	O
(	O
50	O
µg	O
,	O
0	O
.	O
0146	O
µmol	O
)	O
in	O
a	O
1	O
∶	O
1	O
water	O
/	O
methanol	O
solution	O
(	O
280	O
µl	O
).	O

The	O
mixture	O
was	O
left	O
stirring	O
for	O
one	O
hour	O
at	O
40	O
°	O
C	O
and	O
for	O
two	O
days	O
at	O
RT	O
.	O

The	O
compound	O
was	O
purified	O
twice	O
by	O
ultrafiltration	O
in	O
water	O
:	O
methanol	O
:	O
DMSO	O
50	O
∶	O
48	O
∶	O
2	O
versus	O
30	O
,	O
000	O
molecular	O
weight	O
cut	O
-	O
off	O
membranes	O
and	O
then	O
by	O
reverse	O
phase	O
HPLC	O
on	O
a	O
C4	O
column	O
with	O
water	O
(	O
0	O
.	O
1	O
%	O
TFA	O
)	O
and	O
acetonitrile	O
(	O
0	O
.	O
1	O
%	O
TFA	O
)	O
from	O
30	O
to	O
95	O
%	O
over	O
20	O
min	O
at	O
5	O
mL	O
/	O
min	O
.	O

IR	O
(	O
cast	O
on	O
poly	O
(	O
ethylene	O
)):	O
=	O
3295	O
,	O
1658	O
,	O
1545	O
,	O
1471	O
,	O
1203	O
cm	O
−	O
1	O
.	O

No	O
peak	O
at	O
2098	O
cm	O
−	O
1	O
was	O
observed	O
.	O

The	O
functionalization	O
of	O
the	O
gH625	O
-	O
dendrimer	O
was	O
confirmed	O
by	O
determining	O
the	O
amount	O
of	O
peptide	O
attached	O
via	O
UV	O
analysis	O
(	O
εgH625	O
=	O
7000	O
M	O
−	O
1cm	O
−	O
1	O
at	O
λ	O
=	O
280	O
nm	O
)	O
and	O
comparing	O
the	O
result	O
to	O
the	O
amount	O
of	O
dendrimer	O
and	O
peptide	O
initially	O
used	O
for	O
the	O
reaction	O
(	O
18	O
mol	O
peptide	O
per	O
mol	O
dendrimer	O
).	O

The	O
functionalization	O
of	O
the	O
peptidodendrimer	O
,	O
and	O
thus	O
the	O
reaction	O
between	O
the	O
azide	O
and	O
the	O
alkyne	O
,	O
was	O
also	O
confirmed	O
by	O
following	O
the	O
1H	O
NMR	O
(	O
MeOD	O
,	O
600	O
MHz	O
)	O
chemical	O
shift	O
of	O
the	O
triplet	O
representing	O
the	O
CH2N3	O
protons	O
of	O
the	O
dendrimer	O
from	O
3	O
.	O
37	O
to	O
5	O
.	O
34	O
ppm	O
after	O
reaction	O
.	O

Liposome	O
preparation	O

Phospholipids	O
and	O
fluorescent	O
probes	O
were	O
dissolved	O
in	O
organic	O
solvents	O
.	O

Then	O
the	O
solvent	O
was	O
evaporated	O
to	O
obtain	O
a	O
lipid	O
film	O
which	O
was	O
hydrated	O
with	O
an	O
appropriate	O
volume	O
of	O
10	O
mM	O
HEPES	O
buffer	O
at	O
pH	O
7	O
.	O
4	O
.	O

Small	O
unilamellar	O
vesicles	O
(	O
SUVs	O
)	O
was	O
prepared	O
from	O
dry	O
lipid	O
films	O
were	O
suspended	O
in	O
buffer	O
by	O
vortexing	O
for	O
1	O
h	O
,	O
then	O
the	O
lipid	O
suspension	O
was	O
sonicated	O
for	O
30	O
minutes	O
.	O

Lipid	O
concentrations	O
of	O
liposome	O
suspensions	O
were	O
determined	O
by	O
phosphate	O
analysis	O
as	O
previously	O
reported	O
[	O
16	O
].	O

The	O
final	O
lipid	O
concentration	O
was	O
1	O
mM	O
.	O

Tryptophan	O
fluorescence	O
measurements	O

Tryptophan	O
fluorescence	O
increases	O
with	O
an	O
increase	O
of	O
the	O
environment	O
hydrophobicity	O
and	O
a	O
blue	O
shift	O
of	O
the	O
emission	O
maxima	O
was	O
observed	O
.	O

Emission	O
spectra	O
of	O
the	O
gH625	O
peptide	O
and	O
of	O
the	O
gH625	O
-	O
dendrimer	O
(	O
4	O
µM	O
in	O
peptide	O
),	O
containing	O
the	O
tryptophan	O
residue	O
,	O
in	O
the	O
absence	O
or	O
presence	O
of	O
target	O
vesicles	O
(	O
PC	O
/	O
Chol	O
=	O
55	O
/	O
45	O
)	O
were	O
recorded	O
between	O
300	O
and	O
400	O
nm	O
with	O
an	O
excitation	O
wavelength	O
of	O
295	O
nm	O
.	O

The	O
degree	O
of	O
association	O
with	O
the	O
lipid	O
vesicles	O
was	O
determined	O
by	O
adding	O
lipid	O
vesicles	O
to	O
4	O
µM	O
of	O
the	O
desired	O
compounds	O
.	O

Fluorescence	O
intensity	O
was	O
measured	O
as	O
a	O
function	O
of	O
the	O
lipid	O
/	O
peptide	O
molar	O
ratio	O
,	O
in	O
three	O
to	O
four	O
separate	O
experiments	O
.	O

The	O
fluorescence	O
values	O
were	O
corrected	O
by	O
taking	O
into	O
account	O
the	O
dilution	O
factor	O
corresponding	O
to	O
the	O
addition	O
of	O
microliter	O
amounts	O
of	O
liposomes	O
and	O
by	O
subtracting	O
the	O
corresponding	O
blank	O
.	O

The	O
lipid	O
/	O
peptide	O
molar	O
ratio	O
was	O
200	O
∶	O
1	O
.	O

The	O
binding	O
of	O
gH625	O
and	O
gH625	O
-	O
dendrimer	O
to	O
membranes	O
can	O
be	O
described	O
as	O
a	O
partition	O
equilibrium	O
:	O
Xb	O
=	O
KpCf	O
where	O
Kp	O
is	O
the	O
apparent	O
partition	O
coefficient	O
in	O
units	O
of	O
M	O
−	O
1	O
,	O
Xb	O
is	O
the	O
molar	O
ratio	O
of	O
bound	O
molecules	O
per	O
total	O
lipid	O
and	O
Cf	O
is	O
the	O
equilibrium	O
concentration	O
of	O
the	O
free	O
molecules	O
in	O
solution	O
.	O

In	O
order	O
to	O
calculate	O
Xb	O
,	O
we	O
estimated	O
F	O
∞,	O
the	O
fluorescence	O
signal	O
obtained	O
when	O
all	O
the	O
molecules	O
are	O
lipid	O
-	O
bound	O
,	O
either	O
from	O
the	O
plateau	O
region	O
of	O
the	O
titration	O
curve	O
or	O
from	O
a	O
double	O
reciprocal	O
plot	O
of	O
F	O
(	O
total	O
molecule	O
fluorescence	O
)	O
versus	O
CL	O
(	O
total	O
concentration	O
of	O
lipids	O
),	O
as	O
previously	O
suggested	O
by	O
Schwarz	O
et	O
al	O
.	O
[	O
46	O
].	O

(	O
F	O
∞	O
was	O
obtained	O
by	O
extrapolation	O
of	O
a	O
double	O
reciprocal	O
plot	O
of	O
the	O
total	O
molecule	O
fluorescence	O
vs	O
.	O
the	O
total	O
lipid	O
concentration	O
in	O
the	O
outer	O
leaflet	O
,	O
i	O
.	O
e	O
.	O
1	O
/	O
F	O
vs	O
.	O
1	O
/	O
0	O
.	O
6CL	O
).	O

Knowing	O
the	O
fluorescence	O
intensities	O
of	O
the	O
free	O
and	O
bound	O
forms	O
of	O
the	O
molecules	O
of	O
interest	O
,	O
the	O
fraction	O
of	O
membrane	O
-	O
bound	O
molecules	O
,	O
fb	O
,	O
can	O
be	O
determined	O
from	O
fb	O
=	O
(	O
F	O
-	O
F0	O
)/(	O
F	O
∞-	O
F0	O
),	O
where	O
F	O
represents	O
the	O
fluorescence	O
of	O
molecules	O
after	O
the	O
addition	O
of	O
the	O
vesicles	O
and	O
F0	O
represents	O
the	O
fluorescence	O
of	O
the	O
unbound	O
molecules	O
.	O

Determining	O
fb	O
allows	O
us	O
to	O
calculate	O
the	O
equilibrium	O
concentration	O
of	O
free	O
molecules	O
in	O
solution	O
,	O
Cf	O
,	O
as	O
well	O
as	O
the	O
extent	O
of	O
molecules	O
binding	O
Xb	O
.	O

It	O
was	O
assumed	O
that	O
the	O
molecules	O
were	O
initially	O
partitioned	O
only	O
over	O
the	O
outer	O
leaflet	O
of	O
the	O
SUV	O
(	O
60	O
%	O
of	O
the	O
total	O
lipid	O
).	O

Therefore	O
,	O
values	O
of	O
Xb	O
were	O
corrected	O
as	O
follows	O
:	O
Xb	O
*	O
=	O
Xb	O
/	O
0	O
.	O
6	O
.	O

The	O
curve	O
resulting	O
from	O
plotting	O
Xb	O
*	O
versus	O
the	O
concentration	O
of	O
the	O
free	O
molecules	O
,	O
Cf	O
,	O
is	O
referred	O
to	O
as	O
the	O
conventional	O
binding	O
isotherm	O
.	O

Plots	O
of	O
Xb	O
*	O
versus	O
Cf	O
yield	O
straight	O
lines	O
with	O
the	O
slope	O
corresponding	O
to	O
Kp	O
if	O
a	O
simple	O
partition	O
equilibrium	O
is	O
observed	O
.	O

A	O
deviation	O
is	O
expected	O
for	O
the	O
binding	O
of	O
molecules	O
that	O
self	O
-	O
associate	O
at	O
the	O
membrane	O
surface	O
corresponding	O
to	O
binding	O
isotherms	O
that	O
are	O
not	O
straight	O
lines	O
but	O
deviate	O
to	O
increased	O
binding	O
at	O
higher	O
molecule	O
concentrations	O
.	O

If	O
enough	O
data	O
points	O
of	O
Cf	O
can	O
be	O
collected	O
at	O
very	O
low	O
free	O
molecule	O
concentrations	O
,	O
the	O
surface	O
partition	O
coefficients	O
,	O
Kp	O
,	O
can	O
be	O
estimated	O
from	O
the	O
initial	O
slopes	O
of	O
the	O
curves	O
(	O
Figure	O
1	O
).	O

Scheme	O
of	O
the	O
octadecaazide	O
dendrimer	O
synthesis	O
.	O

Tryptophan	O
quenching	O
by	O
acrylamide	O

Aliquots	O
of	O
a	O
4	O
M	O
solution	O
of	O
the	O
water	O
-	O
soluble	O
quencher	O
acrilamide	O
were	O
added	O
to	O
the	O
solution	O
containing	O
gH625	O
or	O
gH625	O
-	O
dendrimer	O
(	O
4	O
µM	O
in	O
peptide	O
)	O
in	O
the	O
absence	O
or	O
presence	O
of	O
liposomes	O
(	O
PC	O
:	O
Chol	O
55	O
∶	O
45	O
,	O
8	O
•	O
10	O
−	O
4	O
M	O
)	O
at	O
a	O
lipid	O
/	O
peptide	O
molar	O
ratio	O
of	O
200	O
:	O
1	O
.	O

The	O
maximal	O
concentration	O
of	O
acrylamide	O
is	O
0	O
.	O
2	O
mM	O
.	O

Fluorescence	O
was	O
measured	O
at	O
an	O
excitation	O
wavelength	O
of	O
295	O
nm	O
to	O
reduce	O
acrylamide	O
absorbance	O
(	O
and	O
the	O
resulting	O
inner	O
filter	O
effect	O
),	O
and	O
emission	O
at	O
a	O
wavelength	O
of	O
340	O
nm	O
to	O
eliminate	O
interference	O
from	O
the	O
Raman	O
band	O
of	O
water	O
.	O

The	O
data	O
were	O
analyzed	O
according	O
to	O
the	O
Stern	O
-	O
Volmer	O
equation	O
[	O
47	O
],	O
F0	O
/	O
F	O
=	O
1	O
+	O
Ksv	O
[	O
Q	O
],	O
where	O
F0	O
and	O
F	O
represent	O
the	O
fluorescence	O
intensities	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
the	O
quencher	O
(	O
Q	O
),	O
respectively	O
,	O
and	O
Ksv	O
is	O
the	O
Stern	O
-	O
Volmer	O
quenching	O
constant	O
,	O
which	O
is	O
a	O
measure	O
of	O
the	O
accessibility	O
of	O
tryptophan	O
to	O
acrylamide	O
.	O

Considering	O
that	O
acrylamide	O
does	O
not	O
significantly	O
partition	O
into	O
the	O
membrane	O
bilayer	O
,	O
the	O
value	O
for	O
Ksv	O
can	O
be	O
considered	O
to	O
be	O
a	O
reliable	O
reflection	O
of	O
the	O
bimolecular	O
rate	O
constant	O
for	O
collisional	O
quenching	O
of	O
the	O
tryptophan	O
residue	O
present	O
in	O
the	O
aqueous	O
phase	O
.	O

Accordingly	O
,	O
Ksv	O
is	O
determined	O
by	O
the	O
amount	O
of	O
non	O
-	O
vesicle	O
-	O
associated	O
free	O
molecule	O
as	O
well	O
as	O
the	O
fraction	O
of	O
the	O
molecule	O
residing	O
on	O
the	O
surface	O
of	O
the	O
bilayer	O
.	O

Tryptophan	O
quenching	O
experiments	O
with	O
Br	O
-	O
PC	O

Tryptophan	O
is	O
sensitive	O
to	O
its	O
environment	O
and	O
has	O
been	O
previously	O
utilized	O
to	O
evaluate	O
peptide	O
localization	O
in	O
the	O
membrane	O
[	O
48	O
].	O

Emission	O
spectra	O
of	O
the	O
gH625	O
-	O
dendrimer	O
in	O
the	O
absence	O
or	O
presence	O
of	O
target	O
vesicles	O
(	O
PC	O
/	O
Chol	O
=	O
55	O
/	O
45	O
)	O
were	O
recorded	O
between	O
300	O
and	O
400	O
nm	O
with	O
an	O
excitation	O
wavelength	O
of	O
295	O
nm	O
.	O

Br	O
-	O
PC	O
employed	O
as	O
quencher	O
of	O
tryptophan	O
fluorescence	O
is	O
suitable	O
for	O
probing	O
membrane	O
insertion	O
of	O
peptides	O
,	O
since	O
it	O
acts	O
over	O
a	O
short	O
distance	O
and	O
does	O
not	O
drastically	O
perturb	O
the	O
membrane	O
[	O
20	O
].	O

The	O
peptidodendrimer	O
was	O
added	O
(	O
final	O
concentration	O
of	O
222	O
nM	O
)	O
to	O
2	O
mL	O
of	O
SUVs	O
,	O
thus	O
establishing	O
a	O
lipid	O
:	O
peptide	O
molar	O
ratio	O
of	O
100	O
∶	O
1	O
.	O

After	O
two	O
minutes	O
of	O
incubation	O
at	O
room	O
temperature	O
,	O
an	O
emission	O
spectrum	O
of	O
the	O
tryptophan	O
was	O
recorded	O
with	O
the	O
excitation	O
set	O
at	O
295	O
nm	O
.	O

SUVs	O
composed	O
of	O
PC	O
/	O
Chol	O
that	O
contained	O
25	O
%	O
of	O
either	O
6	O
,	O
7	O
Br	O
-	O
PC	O
,	O
or	O
9	O
,	O
10	O
Br	O
-	O
PC	O
or	O
11	O
,	O
12	O
Br	O
-	O
PC	O
were	O
used	O
.	O

Three	O
separate	O
experiments	O
were	O
conducted	O
.	O

In	O
control	O
experiments	O
,	O
the	O
peptidodendrimer	O
in	O
PC	O
/	O
Chol	O
(	O
55	O
/	O
45	O
)	O
SUVs	O
without	O
Br	O
-	O
PC	O
were	O
used	O
.	O

Membrane	O
permeability	O
studies	O

Membrane	O
destabilization	O
,	O
in	O
the	O
form	O
of	O
diffusion	O
potential	O
collapse	O
,	O
was	O
detected	O
fluorimetrically	O
as	O
described	O
previously	O
[	O
49	O
].	O

Briefly	O
,	O
a	O
liposome	O
suspension	O
(	O
SUV	O
=	O
PC	O
:	O
Chol	O
55	O
∶	O
45	O
,	O
0	O
.	O
1	O
mM	O
),	O
prepared	O
in	O
“	O
K	O
++	O
buffer	O
”,	O
(	O
50	O
mM	O
K2SO4	O
,	O
25	O
mM	O
HEPES	O
-	O
SO4	O
pH	O
6	O
.	O
8	O
)	O
was	O
added	O
to	O
an	O
isotonic	O
buffer	O
,	O
K	O
+-	O
free	O
buffer	O
(	O
50	O
mM	O
Na2SO4	O
,	O
10	O
mM	O
HEPES	O
-	O
SO4	O
pH	O
6	O
.	O
8	O
),	O
to	O
which	O
the	O
dye	O
diS	O
-	O
C3	O
-	O
5	O
(	O
final	O
concentration	O
1	O
×	O
10	O
−	O
6	O
M	O
)	O
was	O
added	O
.	O

Subsequent	O
addition	O
of	O
valinomycin	O
(	O
final	O
concentration	O
1	O
×	O
10	O
−	O
7	O
M	O
)	O
creates	O
a	O
negative	O
diffusion	O
potential	O
inside	O
the	O
vesicles	O
by	O
a	O
selective	O
efflux	O
of	O
K	O
+	O
ions	O
,	O
resulting	O
in	O
a	O
quenching	O
of	O
the	O
dye	O
'	O
s	O
fluorescence	O
.	O

The	O
addition	O
of	O
a	O
permeable	O
compound	O
induces	O
membrane	O
permeability	O
toward	O
all	O
the	O
ions	O
in	O
solution	O
causing	O
dissipation	O
of	O
the	O
diffusion	O
potential	O
,	O
monitored	O
by	O
an	O
increase	O
of	O
fluorescence	O
.	O

Compound	O
concentrations	O
varied	O
from	O
5	O
10	O
−	O
6	O
M	O
to	O
7	O
10	O
−	O
5	O
M	O
.	O

Fluorescence	O
was	O
monitored	O
using	O
excitation	O
at	O
620	O
nm	O
and	O
emission	O
at	O
670	O
nm	O
.	O

The	O
percentage	O
of	O
fluorescence	O
recovery	O
(	O
Ft	O
)	O
was	O
defined	O
as	O
shown	O
in	O
Equation	O
1	O
.	O

(	O
Eq	O
.	O

(	O
1	O
))	O

Ιt	O
is	O
the	O
fluorescence	O
observed	O
after	O
addition	O
of	O
the	O
dendrimer	O
-	O
peptide	O
at	O
time	O
t	O
,	O
Ι0	O
is	O
the	O
fluorescence	O
after	O
addition	O
of	O
valinomycin	O
,	O
and	O
Ιf	O
is	O
the	O
total	O
fluorescence	O
prior	O
to	O
addition	O
of	O
valinomycin	O
.	O

The	O
peptide	O
melittin	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
experiment	O
.	O

Binding	O
analysis	O
by	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O

SPR	O
experiments	O
were	O
carried	O
out	O
with	O
a	O
BIAcore	O
3000	O
analytical	O
system	O
(	O
Biacore	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
using	O
the	O
HPA	O
sensor	O
chip	O
.	O

The	O
HPA	O
sensor	O
chip	O
contains	O
hydrophobic	O
alkanethiol	O
chains	O
,	O
which	O
are	O
covalently	O
bound	O
to	O
its	O
gold	O
surface	O
,	O
and	O
a	O
lipid	O
heteromonolayer	O
created	O
by	O
introducing	O
liposomes	O
to	O
the	O
chip	O
.	O

The	O
complete	O
coverage	O
of	O
the	O
surface	O
with	O
a	O
polar	O
lipid	O
monolayer	O
generates	O
a	O
membrane	O
-	O
like	O
environment	O
where	O
analytes	O
in	O
aqueous	O
buffer	O
interact	O
with	O
a	O
lipid	O
monolayer	O
.	O

The	O
experimental	O
protocol	O
used	O
,	O
was	O
previously	O
described	O
by	O
Mozsolits	O
et	O
al	O
.	O
[	O
50	O
].	O

The	O
running	O
buffer	O
used	O
for	O
all	O
experiments	O
was	O
5	O
mM	O
HEPES	O
100	O
mM	O
NaCl	O
(	O
pH	O
7	O
.	O
4	O
);	O
the	O
washing	O
solution	O
was	O
40	O
mM	O
N	O
-	O
octyl	O
β	O
-	O
D	O
-	O
glucopyranoside	O
.	O

All	O
solutions	O
were	O
freshly	O
prepared	O
,	O
degassed	O
,	O
and	O
filtered	O
through	O
0	O
.	O
22	O
µm	O
pores	O
.	O

The	O
operating	O
temperature	O
was	O
25	O
°	O
C	O
.	O

After	O
cleaning	O
as	O
indicated	O
by	O
the	O
manufacturers	O
,	O
the	O
BIAcore	O
3000	O
instrument	O
was	O
left	O
running	O
overnight	O
using	O
Milli	O
-	O
Q	O
water	O
as	O
eluent	O
to	O
thoroughly	O
wash	O
all	O
liquid	O
-	O
handling	O
parts	O
of	O
the	O
instrument	O
.	O

The	O
HPA	O
chip	O
was	O
then	O
installed	O
,	O
and	O
the	O
alkanethiol	O
surface	O
was	O
cleaned	O
by	O
an	O
injection	O
of	O
the	O
nonionic	O
detergent	O
N	O
-	O
octyl	O
β	O
-	O
D	O
-	O
glucopyranoside	O
(	O
25	O
µl	O
,	O
40	O
mM	O
)	O
at	O
a	O
flow	O
rate	O
of	O
5	O
µl	O
/	O
min	O
.	O

PC	O
/	O
Chol	O
(	O
55	O
/	O
45	O
w	O
/	O
w	O
)	O
SUVs	O
(	O
80	O
µl	O
,	O
0	O
.	O
5	O
mM	O
)	O
were	O
then	O
applied	O
to	O
the	O
chip	O
surface	O
at	O
a	O
flow	O
rate	O
of	O
2	O
µl	O
/	O
min	O
.	O

To	O
remove	O
any	O
multilamellar	O
structures	O
from	O
the	O
lipid	O
surface	O
,	O
we	O
used	O
NaOH	O
10	O
mM	O
and	O
increased	O
the	O
flow	O
rate	O
to	O
50	O
µl	O
/	O
min	O
,	O
which	O
resulted	O
in	O
a	O
stable	O
baseline	O
corresponding	O
to	O
the	O
lipid	O
monolayer	O
linked	O
to	O
the	O
chip	O
surface	O
.	O

The	O
negative	O
control	O
albumin	O
bovine	O
serum	O
(	O
BSA	O
)	O
was	O
injected	O
(	O
25	O
µl	O
,	O
0	O
.	O
1	O
mg	O
/	O
µl	O
in	O
PBS	O
)	O
to	O
confirm	O
complete	O
coverage	O
of	O
the	O
nonspecific	O
binding	O
sites	O
.	O

gH625	O
-	O
dendrimer	O
solutions	O
at	O
the	O
concentration	O
of	O
0	O
.	O
07	O
,	O
0	O
.	O
11	O
,	O
0	O
.	O
22	O
,	O
0	O
.	O
28	O
,	O
0	O
.	O
33	O
,	O
0	O
.	O
44	O
,	O
0	O
.	O
55	O
nM	O
(	O
75	O
µl	O
at	O
a	O
flow	O
rate	O
of	O
30	O
µl	O
/	O
min	O
)	O
were	O
injected	O
onto	O
the	O
lipid	O
surface	O
.	O

HEPES	O
alone	O
then	O
replaced	O
the	O
peptide	O
solution	O
for	O
15	O
min	O
to	O
allow	O
gH625	O
-	O
dendrimer	O
dissociation	O
.	O

SPR	O
detects	O
changes	O
in	O
the	O
reflective	O
index	O
of	O
the	O
surface	O
layer	O
of	O
peptidodendrimer	O
and	O
lipids	O
in	O
contact	O
with	O
the	O
sensor	O
chip	O
.	O

A	O
sensorgram	O
is	O
obtained	O
by	O
plotting	O
the	O
SPR	O
angle	O
against	O
time	O
.	O

This	O
change	O
in	O
the	O
angle	O
is	O
then	O
translated	O
to	O
response	O
units	O
.	O

Analysis	O
of	O
the	O
peptidodendrimer	O
lipid	O
binding	O
event	O
was	O
performed	O
from	O
a	O
series	O
of	O
sensorgrams	O
collected	O
at	O
different	O
peptide	O
concentrations	O
.	O

The	O
sensorgrams	O
for	O
each	O
gH625	O
-	O
dendrimer	O
lipid	O
interaction	O
were	O
analyzed	O
by	O
curve	O
fitting	O
using	O
numerical	O
integration	O
analysis	O
.	O

The	O
BIA	O
evaluation	O
was	O
used	O
to	O
perform	O
complete	O
kinetic	O
analyses	O
of	O
the	O
gH625	O
-	O
dendrimer	O
sensorgrams	O
and	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
for	O
the	O
peptide	O
alone	O
which	O
were	O
previously	O
reported	O
[	O
18	O
].	O

Isothermal	O
calorimetry	O

Isothermal	O
titration	O
calorimetry	O
was	O
carried	O
out	O
on	O
a	O
MicroCal	O
-	O
ITC	O
200	O
calorimeter	O
.	O

Solutions	O
were	O
degassed	O
under	O
vacuum	O
for	O
ten	O
minutes	O
with	O
gentle	O
stirring	O
prior	O
to	O
use	O
.	O

The	O
heat	O
of	O
dilution	O
values	O
were	O
obtained	O
in	O
control	O
experiments	O
by	O
injecting	O
either	O
the	O
peptidodendrimer	O
or	O
the	O
lipid	O
solutions	O
into	O
buffer	O
and	O
the	O
heats	O
of	O
dilution	O
were	O
substracted	O
from	O
the	O
heats	O
determined	O
in	O
the	O
corresponding	O
peptidodendrimer	O
-	O
lipid	O
experiments	O
.	O

Two	O
kinds	O
of	O
experiments	O
were	O
performed	O
;	O
in	O
the	O
first	O
the	O
calorimeter	O
cell	O
contains	O
lipid	O
vesicles	O
and	O
the	O
peptidodendrimer	O
is	O
injected	O
into	O
the	O
cell	O
(	O
lipid	O
0	O
.	O
033	O
mM	O
and	O
gH625	O
-	O
dendrimer	O
17	O
µM	O
);	O
while	O
in	O
the	O
second	O
,	O
the	O
two	O
solutions	O
are	O
exchanged	O
(	O
gH625	O
-	O
dendrimer	O
2	O
.	O
8	O
µM	O
was	O
placed	O
in	O
the	O
280	O
µL	O
reaction	O
cell	O
,	O
while	O
SUVs	O
2	O
mM	O
(	O
PC	O
:	O
Chol	O
55	O
∶	O
45	O
)	O
in	O
5	O
mM	O
Hepes	O
100	O
mM	O
NaCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
were	O
placed	O
in	O
a	O
40	O
µL	O
syringe	O
).	O

In	O
the	O
second	O
experiment	O
the	O
LUVs	O
were	O
added	O
into	O
the	O
gH625	O
-	O
dendrimer	O
solution	O
via	O
20	O
injections	O
of	O
2	O
µl	O
per	O
injection	O
.	O

The	O
injections	O
were	O
pre	O
-	O
programmed	O
at	O
150	O
sec	O
intervals	O
and	O
were	O
performed	O
automatically	O
at	O
25	O
°	O
C	O
under	O
stirring	O
at	O
1000	O
rpm	O
.	O

The	O
exotermic	O
heat	O
flow	O
(	O
dQ	O
/	O
dt	O
)	O
data	O
were	O
collected	O
every	O
second	O
for	O
the	O
first	O
100	O
sec	O
after	O
each	O
injection	O
and	O
every	O
5	O
sec	O
for	O
the	O
remaining	O
time	O
interval	O
and	O
were	O
analysed	O
using	O
the	O
inbuilt	O
Origin	O
software	O
.	O

Results	O

Synthesis	O
of	O
the	O
gH625	O
-	O
dendrimer	O

The	O
octadecaazide	O
dendrimer	O
was	O
synthetized	O
as	O
previously	O
reported	O
[	O
22	O
]	O
and	O
as	O
shown	O
in	O
Figure	O
1	O
.	O

Briefly	O
,	O
the	O
second	O
generation	O
Newkome	O
-	O
style	O
dendron	O
2	O
was	O
first	O
functionalized	O
at	O
the	O
amine	O
terminus	O
with	O
succinic	O
anhydride	O
to	O
afford	O
the	O
hemisuccinate	O
dendron	O
3	O
.	O

Coupling	O
dendrons	O
2	O
and	O
3	O
by	O
using	O
2	O
-[	O
7	O
-	O
aza	O
-	O
1H	O
-	O
benzotriazol	O
-	O
1	O
-	O
yl	O
]-	O
1	O
,	O
1	O
,	O
3	O
,	O
3	O
-	O
tetramethyluronium	O
hexafluorophosphate	O
(	O
HATU	O
)	O
as	O
coupling	O
agent	O
afforded	O
the	O
symmetrical	O
dendrimer	O
4	O
.	O

Acidic	O
deprotection	O
of	O
the	O
terminal	O
tert	O
-	O
butyl	O
esters	O
resulted	O
in	O
the	O
formation	O
of	O
the	O
octadecaacid	O
dendrimer	O
5	O
.	O

Reaction	O
between	O
the	O
terminal	O
carboxylic	O
acid	O
groups	O
and	O
an	O
azido	O
-	O
terminated	O
amine	O
and	O
an	O
azido	O
-	O
terminated	O
amine	O
linker	O
afforded	O
the	O
octadecaazide	O
dendrimer	O
6	O
(	O
Figure	O
1	O
).	O

The	O
gH625	O
peptide	O
sequence	O
was	O
synthesized	O
with	O
a	O
propargylglycine	O
residue	O
(	O
PrA	O
)	O
at	O
the	O
C	O
terminus	O
to	O
provide	O
a	O
handle	O
for	O
the	O
copper	O
-	O
catalyzed	O
azide	O
–	O
alkyne	O
cycloaddition	O
(	O
CuAAC	O
).	O

Functionalization	O
of	O
the	O
dendrimer	O
was	O
performed	O
in	O
a	O
water	O
/	O
methanol	O
solution	O
(	O
1	O
∶	O
1	O
v	O
/	O
v	O
)	O
by	O
using	O
CuSO4	O
·	O
5H2O	O
as	O
catalyst	O
and	O
sodium	O
ascorbate	O
as	O
reducing	O
agent	O
.	O

The	O
obtained	O
peptide	O
-	O
dendrimer	O
was	O
purified	O
by	O
HPLC	O
as	O
reported	O
in	O
the	O
experimental	O
section	O
.	O

The	O
obtained	O
profiles	O
are	O
reported	O
in	O
Figure	O
2	O
.	O

The	O
amount	O
of	O
peptide	O
functionalization	O
was	O
determined	O
to	O
be	O
71	O
%	O
by	O
UV	O
analysis	O
(	O
ε	O
=	O
7000	O
M	O
−	O
1	O
cm	O
−	O
1	O
at	O
λ	O
=	O
280	O
nm	O
).	O

IR	O
analysis	O
showed	O
the	O
disappearance	O
of	O
the	O
azide	O
stretch	O
at	O
2098	O
cm	O
−	O
1	O
suggesting	O
that	O
all	O
azides	O
were	O
consumed	O
within	O
the	O
instrumental	O
error	O
range	O
,	O
thus	O
suggesting	O
high	O
functionalization	O
of	O
the	O
dendrimer	O
with	O
peptides	O
.	O

Analysis	O
of	O
the	O
NMR	O
spectrum	O
suggested	O
at	O
least	O
57	O
%	O
functionalization	O
,	O
corresponding	O
to	O
10	O
–	O
11	O
peptides	O
per	O
dendrimer	O
,	O
however	O
the	O
actual	O
value	O
is	O
higher	O
due	O
to	O
the	O
peak	O
at	O
3	O
.	O
37	O
ppm	O
overlapping	O
with	O
residual	O
solvent	O
and	O
peptide	O
backbone	O
peaks	O
,	O
and	O
possible	O
suppression	O
of	O
the	O
triazole	O
ring	O
due	O
to	O
aggregation	O
of	O
the	O
dendrimers	O
in	O
solution	O
.	O

These	O
three	O
methods	O
suggest	O
that	O
the	O
degree	O
of	O
functionalization	O
is	O
above	O
70	O
%	O
and	O
potentially	O
quantitative	O
.	O

HPLC	O
traces	O
of	O
gH625	O
-	O
Dendrimer	O
crude	O
(	O
panel	O
A	O
),	O
gH625	O
-	O
Dendrimer	O
pure	O
(	O
panel	O
B	O
),	O
gH625	O
pure	O
(	O
panel	O
C	O
)	O
and	O
dendrimer	O
pure	O
(	O
panel	O
D	O
).	O

Tryptophan	O
fluorescence	O
measurements	O

In	O
order	O
to	O
evaluate	O
the	O
degree	O
of	O
penetration	O
of	O
the	O
gH625	O
-	O
dendrimer	O
into	O
the	O
membrane	O
bilayer	O
we	O
compared	O
the	O
intrinsic	O
fluorescence	O
of	O
gH625	O
alone	O
and	O
of	O
gH625	O
-	O
dendrimer	O
due	O
to	O
the	O
presence	O
of	O
a	O
tryptophan	O
residue	O
in	O
the	O
middle	O
of	O
the	O
peptide	O
sequence	O
.	O

For	O
both	O
of	O
them	O
,	O
we	O
compared	O
the	O
fluorescence	O
emission	O
spectra	O
in	O
the	O
presence	O
of	O
PC	O
/	O
Chol	O
vesicles	O
with	O
that	O
in	O
buffer	O
(	O
Figure	O
3	O
).	O

Binding	O
isotherms	O
obtained	O
plotting	O
Xb	O
*	O
versus	O
Cf	O
for	O
gH625	O
and	O
gH625	O
-	O
Dendrimer	O
.	O

It	O
is	O
widely	O
accepted	O
that	O
the	O
fluorescence	O
emission	O
of	O
tryptophan	O
residues	O
increases	O
when	O
the	O
amino	O
acid	O
penetrates	O
a	O
more	O
hydrophobic	O
environment	O
and	O
the	O
maximal	O
spectral	O
position	O
may	O
be	O
shifted	O
toward	O
shorter	O
wavelengths	O
(	O
blue	O
shift	O
)	O
[	O
48	O
].	O

For	O
both	O
molecules	O
,	O
we	O
observed	O
changes	O
in	O
the	O
spectral	O
properties	O
,	O
suggesting	O
that	O
the	O
tryptophan	O
residue	O
of	O
each	O
of	O
them	O
is	O
located	O
in	O
a	O
less	O
polar	O
environment	O
upon	O
interaction	O
with	O
lipids	O
.	O

Emission	O
intensity	O
was	O
enhanced	O
and	O
the	O
maxima	O
shifted	O
to	O
lower	O
wavelengths	O
;	O
blue	O
shifts	O
of	O
this	O
magnitude	O
have	O
been	O
observed	O
when	O
amphiphilic	O
tryptophan	O
-	O
containing	O
peptides	O
interact	O
with	O
phospholipid	O
bilayers	O
and	O
are	O
consistent	O
with	O
the	O
indole	O
moiety	O
becoming	O
partially	O
immersed	O
in	O
the	O
membrane	O
,	O
further	O
suggesting	O
that	O
the	O
two	O
molecules	O
are	O
capable	O
of	O
penetrating	O
a	O
lipid	O
bilayer	O
[	O
48	O
].	O

A	O
lipid	O
-	O
exposed	O
tryptophan	O
residue	O
located	O
at	O
the	O
center	O
of	O
the	O
hydrocarbon	O
core	O
of	O
a	O
bilayer	O
exhibits	O
a	O
characteristic	O
highly	O
blue	O
shifted	O
emission	O
,	O
with	O
a	O
λmax	O
in	O
the	O
range	O
of	O
315	O
–	O
318	O
nm	O
http	O
://	O
pubs	O
.	O
acs	O
.	O
org	O
/	O
cgi	O
-	O
bin	O
/	O
article	O
.	O
cgi	O
/	O
bichaw	O
/	O
2003	O
/	O
42	O
/	O
i11	O
/	O
html	O
/	O
bi026697d	O
.	O
html	O
-	O
bi026697db00003	O
#	O
bi026697db00003	O
.	O

As	O
a	O
tryptophan	O
residue	O
moves	O
toward	O
the	O
more	O
polar	O
membrane	O
surface	O
,	O
λmax	O
gradually	O
shifts	O
to	O
335	O
–	O
340	O
nm	O
.	O

A	O
smaller	O
blue	O
shift	O
of	O
the	O
fluorescence	O
for	O
a	O
tryptophan	O
at	O
the	O
bilayer	O
center	O
can	O
also	O
be	O
detected	O
upon	O
helix	O
oligomerization	O
inside	O
the	O
membrane	O
.	O

This	O
shift	O
presumably	O
reflects	O
the	O
change	O
in	O
local	O
environment	O
upon	O
replacement	O
of	O
contacts	O
between	O
tryptophan	O
and	O
lipid	O
with	O
contacts	O
between	O
tryptophan	O
and	O
polypeptide	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
tryptophan	O
is	O
located	O
inside	O
the	O
membrane	O
and	O
moreover	O
that	O
oligomerization	O
processes	O
may	O
have	O
taken	O
place	O
.	O

The	O
increase	O
in	O
fluorescence	O
for	O
tryptophan	O
binding	O
to	O
membrane	O
phospholipids	O
was	O
used	O
for	O
the	O
binding	O
isotherms	O
for	O
gH625	O
and	O
the	O
gH625	O
-	O
dendrimer	O
,	O
from	O
which	O
partition	O
coefficients	O
could	O
be	O
calculated	O
.	O

The	O
concentrations	O
of	O
peptides	O
used	O
were	O
low	O
enough	O
to	O
cause	O
minimal	O
aggregation	O
in	O
the	O
aqueous	O
phase	O
and	O
were	O
assumed	O
to	O
not	O
disrupt	O
the	O
bilayer	O
structure	O
.	O

SUV	O
vesicles	O
were	O
used	O
in	O
the	O
assay	O
in	O
order	O
to	O
minimize	O
light	O
scattering	O
effects	O
.	O

To	O
determine	O
the	O
surface	O
partition	O
coefficient	O
,	O
the	O
fluorescence	O
intensities	O
were	O
converted	O
to	O
moles	O
of	O
bound	O
peptide	O
per	O
moles	O
of	O
lipid	O
and	O
plotted	O
as	O
a	O
function	O
of	O
the	O
free	O
peptide	O
concentration	O
as	O
described	O
in	O
material	O
and	O
methods	O
(	O
Figure	O
3	O
).	O

As	O
partition	O
coefficients	O
depend	O
on	O
the	O
concentration	O
of	O
lipid	O
accessible	O
to	O
peptide	O
,	O
the	O
curves	O
obtained	O
by	O
plotting	O
Xb	O
*	O
(	O
the	O
molar	O
ratio	O
of	O
bound	O
peptide	O
per	O
60	O
%	O
of	O
the	O
total	O
lipid	O
)	O
vs	O
Cf	O
(	O
the	O
equilibrium	O
concentration	O
of	O
free	O
peptide	O
in	O
the	O
solution	O
)	O
are	O
referred	O
to	O
as	O
the	O
conventional	O
binding	O
isotherms	O
.	O

We	O
observed	O
a	O
non	O
-	O
linear	O
relationship	O
indicating	O
accumulation	O
of	O
the	O
two	O
compounds	O
on	O
the	O
surface	O
which	O
cannot	O
be	O
explained	O
as	O
a	O
simple	O
phenomenon	O
without	O
cooperative	O
association	O
.	O

This	O
behavior	O
is	O
the	O
hallmark	O
for	O
peptides	O
that	O
self	O
-	O
associate	O
at	O
membrane	O
surfaces	O
upon	O
partitioning	O
.	O

If	O
aggregation	O
occurred	O
only	O
in	O
water	O
but	O
not	O
in	O
the	O
bilayer	O
phase	O
,	O
the	O
opposite	O
course	O
of	O
the	O
isotherms	O
should	O
be	O
expected	O
:	O
a	O
steep	O
rise	O
at	O
the	O
origin	O
,	O
followed	O
by	O
pronounced	O
flattening	O
;	O
thus	O
,	O
the	O
shape	O
of	O
the	O
isotherms	O
obtained	O
could	O
be	O
interpreted	O
as	O
reflecting	O
a	O
process	O
whereby	O
peptides	O
first	O
incorporate	O
into	O
the	O
membrane	O
and	O
then	O
aggregate	O
there	O
within	O
.	O

Moreover	O
,	O
there	O
was	O
no	O
evidence	O
of	O
aggregation	O
in	O
water	O
at	O
the	O
concentration	O
used	O
in	O
this	O
experiment	O
.	O

In	O
the	O
isotherms	O
obtained	O
,	O
the	O
total	O
extent	O
of	O
incorporation	O
(	O
Xb	O
*)	O
slowly	O
increases	O
until	O
a	O
critical	O
concentration	O
is	O
reached	O
,	O
where	O
massive	O
internal	O
aggregation	O
apparently	O
starts	O
to	O
develop	O
.	O

The	O
surface	O
partition	O
coefficients	O
Kp	O
were	O
estimated	O
by	O
extrapolating	O
the	O
initial	O
slopes	O
of	O
the	O
curves	O
to	O
Cf	O
values	O
of	O
zero	O
;	O
curves	O
are	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
Kp	O
values	O
for	O
gH625	O
and	O
gH625	O
-	O
Dendrimer	O
are	O
shown	O
in	O
Table	O
1	O
.	O

The	O
Kp	O
value	O
obtained	O
for	O
gH625	O
is	O
2	O
.	O
8	O
104	O
,	O
indicating	O
that	O
the	O
tryptophan	O
in	O
gH625	O
is	O
embedded	O
in	O
the	O
bilayer	O
and	O
thus	O
that	O
most	O
of	O
the	O
peptide	O
gH625	O
is	O
located	O
inside	O
the	O
bilayer	O
.	O

The	O
Kp	O
value	O
for	O
gH625	O
-	O
dendrimer	O
is	O
3	O
.	O
4	O
104	O
,	O
indicating	O
that	O
also	O
in	O
the	O
functionalized	O
dendrimer	O
the	O
tryptophan	O
residue	O
of	O
the	O
peptide	O
is	O
stably	O
inserted	O
inside	O
the	O
bilayer	O
.	O

Partition	O
coefficient	O
for	O
the	O
binding	O
of	O
gH625	O
and	O
gH625	O
-	O
dendrimer	O
with	O
PC	O
/	O
Chol	O
obtained	O
by	O
fluorescence	O
studies	O
.	O

gH625	O

gH625	O
-	O
dendrimer	O

Kp	O

2	O
.	O
8	O
104	O
±	O
0	O
.	O
2	O

3	O
.	O
4	O
104	O
±	O
0	O
.	O
1	O

Quenching	O
of	O
tryptophan	O
by	O
acrylamide	O

The	O
changes	O
in	O
the	O
tryptophan	O
fluorescence	O
spectra	O
upon	O
binding	O
of	O
gH625	O
and	O
gH625	O
-	O
dendrimer	O
to	O
lipid	O
vesicles	O
indicate	O
their	O
insertion	O
into	O
the	O
hydrophobic	O
bilayer	O
.	O

We	O
further	O
determined	O
the	O
accessibility	O
of	O
the	O
tryptophan	O
residue	O
to	O
acrylamide	O
,	O
a	O
neutral	O
,	O
water	O
-	O
soluble	O
,	O
highly	O
efficient	O
quenching	O
molecule	O
that	O
is	O
unable	O
to	O
penetrate	O
into	O
the	O
hydrophobic	O
core	O
of	O
the	O
lipid	O
bilayer	O
.	O

The	O
more	O
deeply	O
a	O
tryptophan	O
residue	O
is	O
buried	O
,	O
the	O
less	O
strongly	O
it	O
is	O
quenched	O
by	O
acrylamide	O
.	O

Stern	O
-	O
Volmer	O
plots	O
for	O
the	O
quenching	O
of	O
tryptophan	O
by	O
acrylamide	O
in	O
buffer	O
and	O
in	O
PC	O
/	O
Chol	O
LUVs	O
are	O
shown	O
in	O
Figure	O
4	O
.	O

Stern	O
-	O
Volmer	O
plots	O
of	O
acrylamide	O
quenching	O
of	O
gH625	O
and	O
gH625	O
-	O
Dendrimer	O
in	O
buffer	O
(	O
open	O
symbols	O
)	O
and	O
in	O
LUVs	O
(	O
closed	O
symbols	O
).	O

Fluorescence	O
of	O
tryptophan	O
decreased	O
in	O
a	O
concentration	O
dependent	O
manner	O
by	O
the	O
addition	O
of	O
acrylamide	O
to	O
the	O
peptide	O
solution	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
liposomes	O
,	O
without	O
other	O
effects	O
on	O
the	O
spectra	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
liposomes	O
,	O
less	O
decrement	O
in	O
fluorescence	O
intensity	O
was	O
evident	O
,	O
thus	O
revealing	O
that	O
tryptophan	O
is	O
less	O
accessible	O
to	O
the	O
quencher	O
in	O
the	O
presence	O
of	O
LUVs	O
.	O

Ksv	O
values	O
are	O
reported	O
in	O
Table	O
2	O
.	O

Stern	O
-	O
Volmer	O
(	O
Ksv	O
)	O
quenching	O
constant	O
calculated	O
from	O
the	O
equation	O
Fo	O
/	O
F	O
=	O
1	O
+	O
Ksv	O
[	O
Q	O
]	O
(	O
Q	O
,	O
quencher	O
)	O
for	O
gH625	O
and	O
gH625	O
-	O
dendrimer	O
.	O

Ksv	O
(	O
M	O
−	O
1	O
)	O

gH625	O
in	O
Buffer	O

9	O
.	O
70	O
±	O
0	O
.	O
21	O

gH625	O
in	O
LUVs	O

4	O
.	O
98	O
±	O
0	O
.	O
14	O

gH625	O
-	O
dendrimer	O
in	O
Buffer	O

12	O
.	O
60	O
±	O
0	O
.	O
22	O

gH625	O
-	O
dendrimer	O
in	O
SUVs	O

3	O
.	O
04	O
±	O
0	O
.	O
14	O

Analysis	O
of	O
the	O
obtained	O
values	O
confirm	O
that	O
the	O
gH625	O
-	O
dendrimer	O
tryptophans	O
are	O
more	O
exposed	O
than	O
those	O
of	O
gH625	O
in	O
buffer	O
;	O
in	O
fact	O
the	O
Ksv	O
of	O
gH625	O
-	O
dendrimer	O
is	O
higher	O
.	O

On	O
the	O
contrary	O
,	O
the	O
Ksv	O
value	O
in	O
LUVs	O
of	O
gH625	O
-	O
dendrimer	O
is	O
lower	O
,	O
suggesting	O
that	O
tryptophans	O
are	O
more	O
buried	O
in	O
the	O
bilayers	O
,	O
becoming	O
more	O
inaccessible	O
for	O
quenching	O
by	O
acrylamide	O
.	O

Comparison	O
of	O
the	O
plots	O
(	O
Figure	O
4	O
)	O
and	O
of	O
the	O
values	O
of	O
Ksv	O
(	O
Table	O
2	O
)	O
confirms	O
that	O
the	O
tryptophans	O
in	O
gH625	O
-	O
dendrimer	O
are	O
more	O
deeply	O
inserted	O
than	O
in	O
the	O
isolated	O
peptide	O
.	O

Membrane	O
permeability	O
studies	O

Increasing	O
concentrations	O
of	O
gH625	O
and	O
gH625	O
-	O
dendrimer	O
were	O
mixed	O
with	O
the	O
same	O
amount	O
of	O
PC	O
/	O
Chol	O
SUVs	O
pretreated	O
with	O
the	O
fluorescent	O
dye	O
and	O
valinomycin	O
.	O

We	O
did	O
not	O
observe	O
any	O
enhanced	O
recovery	O
of	O
fluorescence	O
(	O
quenched	O
by	O
the	O
addition	O
of	O
valinomycin	O
)	O
with	O
increasing	O
amounts	O
of	O
the	O
two	O
molecules	O
.	O

Our	O
results	O
indicate	O
that	O
there	O
is	O
no	O
electroporation	O
effect	O
due	O
to	O
the	O
peptide	O
or	O
the	O
peptide	O
-	O
dendrimer	O
interactions	O
with	O
the	O
SUVs	O
.	O

Tryptophan	O
quenching	O
experiments	O
with	O
Br	O
-	O
PC	O

The	O
position	O
and	O
the	O
depth	O
of	O
the	O
two	O
molecules	O
inside	O
the	O
bilayer	O
can	O
be	O
investigated	O
by	O
measuring	O
the	O
relative	O
quenching	O
of	O
the	O
fluorescence	O
of	O
the	O
Trp	O
residue	O
by	O
the	O
probes	O
11	O
,	O
12	O
-	O
Br	O
-	O
PC	O
,	O
9	O
,	O
10	O
-	O
Br	O
-	O
PC	O
,	O
and	O
6	O
,	O
7	O
-	O
Br	O
-	O
PC	O
,	O
which	O
differ	O
in	O
the	O
position	O
of	O
the	O
quencher	O
moiety	O
along	O
the	O
hydrocarbon	O
chain	O
.	O

6	O
,	O
7	O
-	O
Br	O
-	O
PC	O
is	O
a	O
better	O
quencher	O
for	O
molecules	O
near	O
or	O
at	O
the	O
interface	O
,	O
while	O
the	O
other	O
two	O
are	O
better	O
probes	O
for	O
molecules	O
buried	O
deeply	O
inside	O
a	O
membrane	O
.	O

We	O
previously	O
reported	O
that	O
the	O
largest	O
quenching	O
of	O
tryptophan	O
fluorescence	O
for	O
gH625	O
was	O
observed	O
with	O
11	O
,	O
12	O
-	O
Br	O
-	O
PC	O
vesicles	O
and	O
9	O
,	O
10	O
-	O
Br	O
-	O
PC	O
,	O
while	O
slightly	O
less	O
quenching	O
was	O
observed	O
with	O
6	O
,	O
7	O
-	O
Br	O
-	O
PC	O
[	O
20	O
].	O

These	O
results	O
indicate	O
that	O
,	O
upon	O
binding	O
to	O
vesicles	O
,	O
gH625	O
inserted	O
into	O
the	O
membrane	O
bilayer	O
with	O
the	O
tryptophan	O
side	O
chain	O
pointing	O
toward	O
the	O
bilayer	O
interior	O
.	O

We	O
observed	O
a	O
different	O
result	O
for	O
the	O
gH625	O
-	O
dendrimer	O
.	O

There	O
is	O
a	O
significant	O
change	O
compared	O
to	O
the	O
control	O
but	O
the	O
three	O
spectra	O
are	O
superimposable	O
,	O
indicating	O
that	O
there	O
is	O
probably	O
a	O
distribution	O
of	O
the	O
molecule	O
inside	O
the	O
bilayer	O
with	O
the	O
tryptophan	O
localized	O
at	O
various	O
depths	O
(	O
Figure	O
5	O
).	O

Percentage	O
of	O
tryptophan	O
fluorescence	O
for	O
gH625	O
−	O
dendrimer	O
in	O
PC	O
/	O
Chol	O
and	O
in	O
the	O
presence	O
of	O
the	O
probes	O
11	O
,	O
12	O
-	O
Br	O
-	O
PC	O
,	O
9	O
,	O
10	O
-	O
Br	O
-	O
PC	O
,	O
and	O
6	O
,	O
7	O
-	O
Br	O
-	O
PC	O
.	O

Binding	O
Analysis	O
by	O
Surface	O
Plasmon	O
Resonance	O
(	O
SPR	O
)	O

We	O
utilized	O
a	O
BIAcore	O
biosensor	O
to	O
investigate	O
the	O
mode	O
of	O
action	O
of	O
gH625	O
-	O
dendrimer	O
and	O
compared	O
it	O
with	O
gH625	O
[	O
18	O
],	O
[	O
19	O
].	O

PC	O
/	O
Chol	O
monolayers	O
were	O
absorbed	O
onto	O
the	O
HPA	O
.	O

Sensorgrams	O
of	O
the	O
binding	O
with	O
monolayers	O
are	O
shown	O
in	O
Figure	O
6	O
.	O

Sensorgrams	O
of	O
the	O
binding	O
between	O
various	O
concentrations	O
of	O
gH625	O
-	O
dendrimer	O
with	O
the	O
HPA	O
chip	O
.	O

The	O
sensorgrams	O
revealed	O
that	O
the	O
RU	O
signal	O
intensity	O
increased	O
as	O
a	O
function	O
of	O
the	O
molecule	O
concentration	O
.	O

This	O
indicates	O
that	O
the	O
amount	O
of	O
molecule	O
bound	O
to	O
the	O
lipids	O
is	O
proportional	O
to	O
its	O
concentration	O
.	O

We	O
employed	O
numerical	O
integration	O
analysis	O
that	O
uses	O
nonlinear	O
analysis	O
to	O
fit	O
an	O
integrated	O
rate	O
equation	O
directly	O
to	O
the	O
sensorgrams	O
[	O
51	O
].	O

When	O
fitting	O
the	O
sensorgrams	O
globally	O
with	O
the	O
simplest	O
1	O
∶	O
1	O
Langmuir	O
binding	O
model	O
,	O
a	O
poor	O
fit	O
was	O
obtained	O
(	O
χ2	O
>	O
50	O
),	O
confirming	O
that	O
this	O
model	O
does	O
not	O
represent	O
the	O
lipid	O
binding	O
mechanism	O
of	O
the	O
gH625	O
-	O
dendrimer	O
.	O

However	O
,	O
a	O
significantly	O
improved	O
fit	O
was	O
obtained	O
using	O
numerical	O
integration	O
of	O
the	O
two	O
-	O
state	O
reaction	O
model	O
of	O
the	O
binding	O
sensorgrams	O
,	O
suggesting	O
that	O
,	O
in	O
analogy	O
with	O
the	O
data	O
previously	O
obtained	O
for	O
the	O
peptide	O
alone	O
[	O
19	O
],	O
there	O
are	O
likely	O
to	O
be	O
at	O
least	O
two	O
steps	O
involved	O
in	O
the	O
interaction	O
between	O
the	O
gH625	O
-	O
dendrimer	O
and	O
the	O
hybrid	O
bilayer	O
membrane	O
surface	O
.	O

In	O
analogy	O
with	O
previous	O
studies	O
of	O
peptide	O
-	O
membrane	O
interactions	O
using	O
SPR	O
[	O
19	O
],	O
[	O
50	O
],	O
[	O
52	O
],	O
the	O
first	O
step	O
may	O
correspond	O
to	O
the	O
actual	O
binding	O
to	O
the	O
surface	O
,	O
while	O
the	O
second	O
step	O
might	O
be	O
the	O
insertion	O
into	O
the	O
hydrophobic	O
core	O
of	O
the	O
membrane	O
.	O

A	O
set	O
of	O
sensorgrams	O
with	O
different	O
gH625	O
-	O
dendrimer	O
concentrations	O
was	O
used	O
to	O
estimate	O
the	O
kinetic	O
parameters	O
.	O

The	O
average	O
values	O
for	O
the	O
rate	O
constants	O
obtained	O
from	O
the	O
two	O
-	O
state	O
model	O
analysis	O
are	O
listed	O
in	O
Table	O
3	O
along	O
with	O
the	O
affinity	O
constant	O
values	O
(	O
KA	O
)	O
and	O
compared	O
with	O
the	O
data	O
previously	O
obtained	O
for	O
the	O
peptide	O
gH625	O
[	O
18	O
].	O

Association	O
(	O
ka1	O
,	O
ka2	O
)	O
and	O
dissociation	O
(	O
kd1	O
,	O
kd2	O
)	O
rate	O
constants	O
obtained	O
for	O
the	O
HPA	O
chip	O
using	O
the	O
two	O
state	O
model	O
.	O

gH625	O

gH625	O
-	O
dendrimer	O

ka1	O

(	O
5	O
.	O
11	O
±	O
0	O
.	O
03	O
)	O
101	O

(	O
6	O
.	O
57	O
±	O
0	O
.	O
02	O
)	O
103	O

kd1	O

(	O
2	O
.	O
51	O
±	O
0	O
.	O
05	O
)	O
10	O
−	O
2	O

(	O
6	O
.	O
95	O
±	O
0	O
.	O
03	O
)	O
10	O
−	O
2	O

K1	O

2	O
.	O
0	O
103	O

9	O
.	O
4	O
104	O

ka2	O

(	O
5	O
.	O
22	O
±	O
0	O
.	O
05	O
)	O
10	O
−	O
3	O

(	O
1	O
.	O
61	O
±	O
0	O
.	O
05	O
)	O
10	O
−	O
2	O

kd2	O

(	O
110	O
±	O
0	O
.	O
06	O
)	O
10	O
−	O
4	O

(	O
4	O
.	O
93	O
±	O
0	O
.	O
09	O
)	O
10	O
−	O
3	O

K2	O

47	O

3	O
.	O
2	O

KA	O

1	O
.	O
00	O
105	O

4	O
.	O
03	O
105	O

The	O
affinity	O
constants	O
K1	O
and	O
K2	O
are	O
for	O
the	O
first	O
(	O
K1	O
=	O
ka1	O
/	O
kd1	O
)	O
and	O
for	O
the	O
second	O
(	O
K2	O
=	O
ka2	O
/	O
kd2	O
)	O
steps	O
respectively	O
,	O
and	O
the	O
affinity	O
constant	O
(	O
KA	O
)	O
determined	O
as	O
(	O
ka1	O
/	O
kd1	O
)	O
×	O
(	O
ka2	O
/	O
kd2	O
)	O
is	O
for	O
the	O
complete	O
binding	O
process	O
.	O

Standard	O
deviations	O
are	O
reported	O
in	O
brackets	O
.	O

The	O
data	O
indicate	O
the	O
main	O
influence	O
on	O
the	O
overall	O
binding	O
constant	O
of	O
the	O
fast	O
association	O
rate	O
and	O
slow	O
dissociation	O
rate	O
of	O
the	O
first	O
step	O
.	O

If	O
this	O
step	O
corresponds	O
to	O
the	O
electrostatic	O
interaction	O
,	O
these	O
results	O
suggest	O
that	O
electrostatic	O
forces	O
play	O
an	O
important	O
role	O
in	O
the	O
binding	O
of	O
membrane	O
-	O
active	O
peptides	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
gH625	O
and	O
gH625	O
-	O
dendrimer	O
have	O
high	O
K1	O
,	O
indicative	O
of	O
the	O
first	O
step	O
corresponding	O
to	O
the	O
electrostatic	O
interaction	O
is	O
important	O
for	O
the	O
binding	O
and	O
the	O
higher	O
value	O
for	O
gH625	O
-	O
dendrimer	O
is	O
probably	O
influenced	O
by	O
the	O
presence	O
of	O
several	O
peptide	O
molecules	O
on	O
the	O
same	O
dendrimer	O
.	O

The	O
overall	O
binding	O
to	O
the	O
membrane	O
bilayer	O
is	O
thus	O
stronger	O
for	O
the	O
gH625	O
-	O
dendrimer	O
.	O

Isothermal	O
calorimetry	O

Isothermal	O
calorimetry	O
can	O
be	O
applied	O
to	O
study	O
membrane	O
interactions	O
in	O
two	O
different	O
modes	O
.	O

In	O
the	O
first	O
,	O
the	O
calorimeter	O
cell	O
contains	O
lipid	O
vesicles	O
and	O
the	O
ligand	O
is	O
injected	O
into	O
the	O
calorimeter	O
cell	O
,	O
while	O
in	O
the	O
second	O
,	O
the	O
two	O
solutions	O
are	O
exchanged	O
.	O

The	O
two	O
experiments	O
provide	O
different	O
thermodynamic	O
parameters	O
.	O

The	O
first	O
type	O
of	O
experiment	O
allows	O
to	O
measure	O
the	O
reaction	O
enthalpy	O
ΔH	O
(	O
Figure	O
7	O
).	O

Isothermal	O
titration	O
calorimetry	O
of	O
SUVs	O
with	O
gH625	O
-	O
dendrimer	O
at	O
25	O
°	O
C	O
.	O

The	O
upper	O
panel	O
shows	O
the	O
calorimeter	O
trace	O
;	O
the	O
lower	O
panel	O
shows	O
the	O
molar	O
enthalpy	O
as	O
evaluated	O
by	O
integration	O
of	O
the	O
calorimeter	O
traces	O
.	O

In	O
the	O
second	O
experiment	O
,	O
after	O
each	O
addition	O
of	O
lipid	O
,	O
the	O
ligand	O
is	O
bound	O
to	O
the	O
lipid	O
vesicles	O
and	O
removed	O
from	O
bulk	O
solution	O
;	O
as	O
a	O
consequence	O
,	O
with	O
increasing	O
lipid	O
concentration	O
in	O
the	O
reaction	O
vessel	O
,	O
less	O
and	O
less	O
ligand	O
is	O
available	O
for	O
binding	O
and	O
the	O
heat	O
of	O
reaction	O
is	O
no	O
longer	O
constant	O
but	O
decreases	O
with	O
each	O
lipid	O
injection	O
.	O

The	O
ΔH	O
values	O
determined	O
in	O
the	O
two	O
experiments	O
should	O
be	O
identical	O
,	O
but	O
the	O
additional	O
advantage	O
of	O
the	O
second	O
type	O
of	O
experiment	O
is	O
the	O
ability	O
to	O
measure	O
the	O
binding	O
isotherm	O
and	O
to	O
evaluate	O
the	O
binding	O
constant	O
K	O
.	O

The	O
enthalpy	O
change	O
upon	O
binding	O
of	O
the	O
gH625	O
-	O
dendrimer	O
to	O
lipid	O
vesicles	O
was	O
measured	O
from	O
the	O
first	O
type	O
of	O
experiment	O
by	O
injecting	O
small	O
aliquots	O
of	O
a	O
gH625	O
-	O
dendrimer	O
solution	O
into	O
concentrated	O
SUVs	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
lipid	O
is	O
in	O
large	O
excess	O
over	O
the	O
ligand	O
during	O
the	O
whole	O
experiment	O
and	O
the	O
injected	O
ligand	O
is	O
completely	O
bound	O
to	O
the	O
membrane	O
surface	O
if	O
the	O
binding	O
constant	O
is	O
sufficiently	O
large	O
.	O

Each	O
injection	O
experiment	O
thus	O
produces	O
the	O
same	O
heat	O
of	O
reaction	O
,	O
Δh	O
.	O
Figure	O
7	O
shows	O
the	O
result	O
of	O
the	O
injection	O
of	O
2	O
µl	O
aliquots	O
of	O
the	O
0	O
.	O
017	O
mM	O
gH625	O
-	O
dendrimer	O
solution	O
(	O
buffer	O
:	O
Hepes	O
5	O
mM	O
,	O
NaCl	O
100	O
mM	O
,	O
pH	O
7	O
.	O
4	O
)	O
into	O
0	O
.	O
033	O
mM	O
PC	O
:	O
Chol	O
(	O
55	O
∶	O
45	O
)	O
SUVs	O
at	O
25	O
°	O
C	O
.	O

The	O
average	O
heat	O
of	O
reaction	O
observed	O
after	O
subtraction	O
of	O
the	O
heat	O
of	O
dilution	O
(	O
measured	O
in	O
control	O
experiments	O
of	O
peptidodendrimer	O
into	O
buffer	O
injection	O
)	O
was	O
−	O
1	O
.	O
5	O
µcal	O
.	O

The	O
analysis	O
of	O
the	O
heat	O
of	O
reactions	O
shows	O
that	O
the	O
reaction	O
is	O
exothermic	O
.	O

Dividing	O
the	O
heat	O
of	O
reaction	O
by	O
the	O
amount	O
of	O
injected	O
molecule	O
yields	O
the	O
molar	O
enthalpy	O
of	O
binding	O
,	O
ΔH	O
(−	O
47	O
.	O
5	O
Kcal	O
/	O
mol	O
)	O
(	O
Figure	O
7	O
).	O

In	O
the	O
second	O
experiment	O
,	O
the	O
gH625	O
-	O
dendrimer	O
was	O
contained	O
in	O
the	O
calorimeter	O
cell	O
and	O
lipid	O
vesicles	O
were	O
injected	O
.	O

This	O
allowed	O
the	O
determination	O
of	O
the	O
binding	O
isotherm	O
.	O

The	O
molecule	O
was	O
employed	O
at	O
a	O
concentration	O
of	O
2	O
.	O
8	O
µM	O
and	O
each	O
titration	O
peak	O
corresponds	O
to	O
a	O
2	O
µl	O
injection	O
of	O
a	O
2	O
mM	O
SUVs	O
(	O
20	O
injections	O
)	O
except	O
the	O
first	O
one	O
that	O
corresponds	O
to	O
a	O
0	O
.	O
4	O
µl	O
injection	O
.	O

The	O
amount	O
of	O
heat	O
released	O
decreases	O
with	O
increasing	O
injection	O
number	O
as	O
less	O
and	O
less	O
gH625	O
-	O
dendrimer	O
remains	O
free	O
in	O
solution	O
.	O

The	O
heat	O
of	O
reaction	O
values	O
are	O
shown	O
in	O
Figure	O
8	O
after	O
subtraction	O
of	O
the	O
heats	O
of	O
dilution	O
obtained	O
in	O
control	O
experiments	O
of	O
vesicle	O
-	O
into	O
-	O
buffer	O
titrations	O
.	O

Isothermal	O
titration	O
calorimetry	O
of	O
gH625	O
-	O
dendrimer	O
with	O
SUVs	O
at	O
25	O
°	O
C	O
.	O

The	O
upper	O
panel	O
shows	O
the	O
calorimeter	O
trace	O
;	O
the	O
lower	O
panel	O
shows	O
the	O
molar	O
enthalpy	O
as	O
evaluated	O
by	O
integration	O
of	O
the	O
calorimeter	O
traces	O
.	O

If	O
we	O
denote	O
with	O
Δh	O
the	O
experimentally	O
measured	O
heat	O
of	O
reaction	O
at	O
the	O
kth	O
injection	O
,	O
then	O
Σk	O
1Δhk	O
is	O
the	O
cumulative	O
heat	O
of	O
the	O
first	O
k	O
injections	O
and	O
Σn	O
1Δhk	O
is	O
the	O
total	O
heat	O
of	O
injection	O
provided	O
Δhk	O
,	O
the	O
last	O
injection	O
step	O
,	O
is	O
zero	O
.	O

It	O
is	O
possible	O
to	O
calculate	O
the	O
molar	O
heat	O
of	O
reaction	O
,	O
ΔH	O
,	O
according	O
to	O
:	O
where	O
n	O
is	O
the	O
molar	O
amount	O
of	O
the	O
molecule	O
in	O
the	O
calorimeter	O
cell	O
after	O
n	O
injections	O
.	O

The	O
ΔH	O
values	O
determined	O
in	O
the	O
two	O
experiments	O
should	O
be	O
identical	O
.	O

However	O
,	O
the	O
additional	O
advantage	O
of	O
the	O
second	O
type	O
of	O
titration	O
experiment	O
is	O
the	O
possibility	O
to	O
measure	O
the	O
binding	O
isotherm	O
and	O
to	O
evaluate	O
the	O
binding	O
constant	O
K	O
.	O

The	O
binding	O
isotherm	O
reports	O
the	O
dependence	O
of	O
the	O
molar	O
ratio	O
of	O
bound	O
molecule	O
per	O
total	O
lipid	O
,	O
Xb	O
,	O
on	O
the	O
free	O
molecule	O
concentration	O
in	O
solution	O
,	O
Cf	O
,	O
and	O
can	O
be	O
derived	O
using	O
established	O
procedures	O
[	O
53	O
].	O

As	O
for	O
the	O
fluorescence	O
data	O
,	O
Xb	O
*	O
was	O
calculated	O
on	O
the	O
basis	O
of	O
the	O
lipid	O
present	O
in	O
the	O
outer	O
leaflet	O
of	O
the	O
bilayer	O
only	O
since	O
the	O
molecule	O
cannot	O
cross	O
the	O
bilayer	O
under	O
the	O
present	O
experimental	O
conditions	O
.	O

The	O
two	O
essential	O
parameters	O
which	O
constitute	O
the	O
binding	O
isotherm	O
,	O
namely	O
the	O
degree	O
of	O
binding	O
Xb	O
*	O
and	O
the	O
corresponding	O
free	O
molecule	O
concentration	O
Cf	O
can	O
thus	O
be	O
determined	O
in	O
a	O
single	O
titration	O
experiment	O
.	O

Hence	O
the	O
peptidodendrimer	O
lipid	O
-	O
binding	O
equilibrium	O
is	O
Xb	O
*	O
=	O
f	O
(	O
Cf	O
),	O
where	O
f	O
(	O
Cf	O
)	O
describes	O
the	O
functional	O
dependence	O
of	O
Xb	O
*	O
on	O
Cf	O
.	O

The	O
exact	O
form	O
of	O
the	O
functional	O
dependence	O
depends	O
on	O
the	O
nature	O
of	O
the	O
problem	O
and	O
provides	O
information	O
on	O
the	O
organization	O
of	O
the	O
molecule	O
within	O
the	O
membrane	O
as	O
was	O
previously	O
discussed	O
for	O
fluorescence	O
data	O
.	O

A	O
linear	O
relationship	O
is	O
the	O
exception	O
rather	O
than	O
the	O
rule	O
;	O
a	O
straight	O
line	O
indicates	O
a	O
simple	O
adhesion	O
process	O
.	O

The	O
shape	O
of	O
the	O
binding	O
isotherm	O
was	O
not	O
linear	O
indicating	O
that	O
the	O
gH625	O
-	O
dendrimer	O
accumulation	O
at	O
the	O
surface	O
is	O
a	O
complex	O
phenomenon	O
.	O

In	O
particular	O
,	O
also	O
from	O
isothermal	O
calorimetry	O
we	O
obtained	O
a	O
binding	O
isotherm	O
characterized	O
by	O
a	O
flattening	O
at	O
the	O
origin	O
,	O
followed	O
by	O
steep	O
rise	O
,	O
which	O
could	O
be	O
interpreted	O
as	O
reflecting	O
a	O
process	O
whereby	O
peptides	O
first	O
incorporate	O
into	O
the	O
membrane	O
and	O
then	O
aggregate	O
within	O
.	O

In	O
our	O
isotherms	O
,	O
the	O
total	O
extent	O
of	O
incorporation	O
(	O
Xb	O
*)	O
slowly	O
increases	O
until	O
a	O
critical	O
concentration	O
is	O
reached	O
,	O
where	O
massive	O
internal	O
aggregation	O
apparently	O
starts	O
to	O
develop	O
(	O
Figure	O
9	O
).	O

Binding	O
isotherms	O
for	O
binding	O
of	O
gH625	O
-	O
dendrimer	O
to	O
SUVs	O
at	O
25	O
°	O
C	O
.	O

Binding	O
isotherms	O
were	O
derived	O
from	O
lipid	O
into	O
peptidodendrimer	O
titrations	O
as	O
described	O
in	O
the	O
text	O
.	O

The	O
degree	O
of	O
binding	O
is	O
plotted	O
against	O
the	O
free	O
peptidodendrimer	O
concentration	O
.	O

The	O
solid	O
line	O
corresponds	O
to	O
the	O
theoretical	O
binding	O
isotherm	O
.	O

The	O
surface	O
partition	O
coefficient	O
Kp	O
was	O
estimated	O
by	O
extrapolating	O
the	O
initial	O
slopes	O
of	O
the	O
curves	O
to	O
Cf	O
values	O
of	O
zero	O
.	O

The	O
values	O
of	O
Kp	O
(	O
4	O
.	O
3	O
104	O
)	O
obtained	O
are	O
within	O
the	O
range	O
of	O
those	O
obtained	O
for	O
membrane	O
-	O
permeating	O
bioactive	O
peptides	O
and	O
its	O
high	O
value	O
indicates	O
that	O
the	O
tryptophans	O
of	O
gH625	O
-	O
dendrimer	O
are	O
embedded	O
in	O
the	O
bilayer	O
.	O

Knowledge	O
of	O
the	O
partition	O
constant	O
allows	O
the	O
calculation	O
of	O
the	O
free	O
energy	O
of	O
binding	O
according	O
to	O
ΔG	O
=	O
-	O
RTln	O
(	O
55	O
.	O
5	O
K	O
),	O
yielding	O
ΔG	O
=	O
-	O
8	O
.	O
6Kcal	O
/	O
mol	O
(	O
Table	O
4	O
).	O

The	O
factor	O
55	O
.	O
5	O
corrects	O
the	O
cratic	O
contribution	O
since	O
the	O
concentration	O
of	O
the	O
macromolecule	O
in	O
solution	O
is	O
measured	O
in	O
moles	O
per	O
liter	O
and	O
that	O
in	O
the	O
membrane	O
phase	O
in	O
moles	O
of	O
macromolecule	O
per	O
mole	O
of	O
lipid	O
[	O
54	O
].	O

The	O
relation	O
ΔG	O
=	O
ΔH	O
-	O
TΔS	O
,	O
allows	O
the	O
calculation	O
of	O
ΔS	O
=	O
−	O
130	O
cal	O
/	O
mol	O
K	O
.	O

Considering	O
the	O
complex	O
interaction	O
of	O
the	O
gH625	O
-	O
dendrimer	O
with	O
the	O
bilayer	O
,	O
we	O
may	O
consider	O
that	O
this	O
constant	O
is	O
model	O
independent	O
and	O
describes	O
the	O
overall	O
behavior	O
.	O

We	O
obtained	O
a	O
considerably	O
favorable	O
enthalpic	O
contribution	O
and	O
a	O
unfavorable	O
entropic	O
contribution	O
.	O

This	O
unfavorable	O
entropy	O
change	O
may	O
be	O
attributed	O
to	O
the	O
conformational	O
change	O
of	O
gH625	O
from	O
an	O
unordered	O
structure	O
in	O
aqueous	O
solution	O
to	O
an	O
ordered	O
α	O
-	O
helix	O
upon	O
interaction	O
with	O
the	O
membrane	O
as	O
previously	O
shown	O
by	O
circular	O
dichroism	O
data	O
in	O
membrane	O
mimetic	O
environment	O
[	O
22	O
]	O
and	O
as	O
reported	O
in	O
literature	O
for	O
other	O
peptides	O
[	O
55	O
],	O
[	O
56	O
].	O

Nevertheless	O
,	O
the	O
overall	O
free	O
energy	O
change	O
is	O
still	O
large	O
.	O

Partition	O
coefficient	O
for	O
the	O
binding	O
of	O
gH625	O
-	O
dendrimer	O
with	O
PC	O
/	O
Chol	O
obtained	O
by	O
isothermal	O
calorimetry	O
.	O

Method	O
used	O
for	O
calculations	O

ΔH	O
(	O
Kcal	O
/	O
mol	O
)	O

K	O

ΔG	O
(	O
Kcal	O
/	O
mol	O
)	O

TΔS	O
(	O
Kcal	O
/	O
mol	O
)	O

ΔS	O
(	O
cal	O
/	O
mol	O
K	O
)	O

Isothermal	O
binding	O
curve	O

−	O
47	O
.	O
5	O
±	O
0	O
.	O
9	O
[	O
a	O
]	O

4	O
.	O
3	O
104	O

−	O
8	O
.	O
6	O

−	O
38	O
.	O
7	O

−	O
130	O

One	O
site	O
Binding	O

−	O
48	O
±	O
3	O

1	O
.	O
0	O
104	O

−	O
5	O
.	O
4	O

−	O
42	O
.	O
6	O

−	O
143	O

Sequential	O
site	O
binding	O

−	O
6	O
.	O
3	O
±	O
0	O
.	O
5	O

7	O
.	O
6	O
104	O

−	O
6	O
.	O
6	O

+	O
0	O
.	O
3	O

1	O

−	O
47	O
.	O
3	O
±	O
0	O
.	O
3	O

2	O
.	O
9	O
103	O

−	O
4	O
.	O
7	O

−	O
42	O
.	O
6	O

−	O
143	O

This	O
value	O
is	O
the	O
one	O
obtained	O
from	O
the	O
titration	O
of	O
the	O
lipid	O
with	O
the	O
macromolecule	O
.	O

In	O
analogy	O
with	O
the	O
SPR	O
analysis	O
,	O
we	O
decided	O
to	O
interpolate	O
the	O
experimental	O
data	O
reported	O
in	O
Figure	O
7	O
with	O
two	O
different	O
models	O
:	O
the	O
one	O
site	O
binding	O
and	O
the	O
sequential	O
binding	O
site	O
.	O

From	O
the	O
one	O
binding	O
site	O
we	O
obtained	O
a	O
high	O
χ2	O
and	O
thus	O
thermodynamic	O
parameters	O
similar	O
to	O
those	O
obtained	O
from	O
the	O
isothermal	O
binding	O
curve	O
but	O
with	O
a	O
high	O
standard	O
deviation	O
.	O

When	O
we	O
used	O
the	O
sequential	O
binding	O
(	O
for	O
2	O
sites	O
)	O
we	O
obtained	O
lower	O
χ2	O
.	O

The	O
thermodynamic	O
parameters	O
are	O
indicative	O
of	O
an	O
initial	O
interaction	O
with	O
the	O
bilayer	O
with	O
a	O
negative	O
enthalpic	O
change	O
(−	O
6	O
.	O
3	O
Kcal	O
/	O
mol	O
)	O
which	O
is	O
in	O
the	O
typical	O
range	O
of	O
membrane	O
interactions	O
(	O
from	O
−	O
2	O
to	O
−	O
10	O
)	O
[	O
53	O
]	O
and	O
a	O
small	O
favorable	O
entropic	O
component	O
(	O
1	O
Kcal	O
/	O
mol	O
)	O
which	O
may	O
be	O
attributed	O
to	O
the	O
partition	O
from	O
water	O
into	O
a	O
nonpolar	O
environment	O
due	O
to	O
the	O
release	O
of	O
the	O
hydration	O
shell	O
.	O

The	O
second	O
step	O
may	O
correspond	O
to	O
the	O
insertion	O
and	O
the	O
conformational	O
change	O
inside	O
the	O
bilayer	O
.	O

The	O
enthalpic	O
contribution	O
is	O
very	O
favorable	O
while	O
the	O
entropic	O
contribution	O
is	O
negative	O
.	O

These	O
results	O
are	O
similar	O
to	O
those	O
obtained	O
for	O
membrane	O
interacting	O
peptides	O
and	O
has	O
been	O
previously	O
attributed	O
to	O
the	O
formation	O
of	O
an	O
α	O
-	O
helix	O
in	O
the	O
membrane	O
bilayer	O
[	O
57	O
].	O

The	O
high	O
binding	O
constant	O
for	O
this	O
step	O
may	O
allow	O
us	O
to	O
conclude	O
that	O
membrane	O
-	O
facilitated	O
helix	O
formation	O
is	O
a	O
strong	O
driving	O
force	O
for	O
the	O
gH625	O
-	O
dendrimer	O
binding	O
to	O
the	O
lipid	O
membrane	O
.	O

Conclusions	O

Dendrimers	O
are	O
well	O
-	O
defined	O
highly	O
branched	O
structures	O
that	O
have	O
attracted	O
much	O
interest	O
in	O
the	O
biomedical	O
field	O
[	O
58	O
],	O
[	O
59	O
],	O
[	O
60	O
],	O
[	O
61	O
].	O

Among	O
their	O
potential	O
biomedical	O
applications	O
are	O
drug	O
delivery	O
across	O
the	O
cell	O
membrane	O
,	O
a	O
complex	O
structure	O
composed	O
of	O
lipids	O
and	O
embedded	O
proteins	O
.	O

In	O
order	O
to	O
understand	O
dendrimer	O
'	O
s	O
mechanism	O
of	O
action	O
and	O
to	O
increase	O
their	O
targeting	O
efficiency	O
,	O
the	O
interaction	O
with	O
lipid	O
bilayers	O
needs	O
to	O
be	O
unravelled	O
.	O

Model	O
membranes	O
,	O
like	O
liposomes	O
,	O
represent	O
outstanding	O
models	O
due	O
to	O
their	O
simple	O
composition	O
,	O
ease	O
of	O
preparation	O
and	O
good	O
stability	O
.	O

Many	O
reports	O
are	O
dedicated	O
to	O
the	O
study	O
of	O
interactions	O
between	O
dendrimers	O
and	O
biological	O
membranes	O
.	O

The	O
type	O
and	O
strength	O
of	O
the	O
interaction	O
is	O
dependent	O
on	O
charge	O
and	O
size	O
of	O
the	O
molecule	O
.	O

Evidences	O
suggest	O
that	O
dendrimers	O
either	O
create	O
holes	O
in	O
a	O
bilayer	O
[	O
29	O
],	O
[	O
30	O
],	O
[	O
31	O
],	O
[	O
32	O
],	O
[	O
33	O
],	O
[	O
39	O
],	O
[	O
62	O
],	O
[	O
63	O
],	O
[	O
64	O
]	O
or	O
can	O
be	O
incorporated	O
into	O
lipid	O
structure	O
[	O
35	O
],	O
[	O
37	O
],	O
[	O
45	O
],	O
[	O
65	O
].	O

Higher	O
generation	O
dendrimers	O
cause	O
greater	O
disturbances	O
in	O
a	O
lipid	O
bilayer	O
and	O
positively	O
charged	O
dendrimers	O
interact	O
more	O
effectively	O
with	O
liposomes	O
[	O
28	O
],	O
[	O
35	O
],	O
[	O
42	O
],	O
[	O
43	O
],	O
[	O
44	O
],	O
[	O
45	O
].	O

It	O
has	O
been	O
proposed	O
that	O
at	O
low	O
concentrations	O
,	O
dendrimers	O
can	O
traverse	O
the	O
bilayer	O
,	O
whereas	O
at	O
higher	O
concentrations	O
,	O
dendrimer	O
:	O
lipid	O
micelles	O
are	O
created	O
[	O
63	O
],	O
[	O
66	O
].	O

The	O
toxicity	O
of	O
PAMAM	O
dendrimers	O
generally	O
increases	O
with	O
increasing	O
generation	O
number	O
,	O
which	O
has	O
been	O
attributed	O
to	O
the	O
increased	O
number	O
of	O
positive	O
charges	O
per	O
molar	O
concentration	O
and	O
thus	O
increased	O
contact	O
area	O
of	O
the	O
dendrimer	O
with	O
the	O
cell	O
membrane	O
[	O
29	O
].	O

The	O
electrostatic	O
interactions	O
of	O
cationic	O
dendrimers	O
with	O
cell	O
membranes	O
probably	O
induces	O
nano	O
-	O
scale	O
hole	O
formation	O
and	O
membrane	O
destabilization	O
mechanisms	O
[	O
29	O
],	O
[	O
30	O
],	O
[	O
67	O
].	O

It	O
is	O
thus	O
necessary	O
to	O
remove	O
positive	O
charges	O
,	O
through	O
the	O
functionalization	O
of	O
external	O
groups	O
,	O
from	O
the	O
surface	O
of	O
the	O
dendrimer	O
[	O
68	O
]	O
to	O
achieve	O
better	O
cytotoxicity	O
profiles	O
.	O

In	O
this	O
contribution	O
,	O
we	O
present	O
a	O
dendrimer	O
with	O
the	O
external	O
termini	O
modified	O
by	O
a	O
peptide	O
,	O
which	O
has	O
been	O
proved	O
to	O
enhance	O
cell	O
membrane	O
crossing	O
[	O
14	O
],	O
[	O
69	O
],	O
[	O
70	O
].	O

The	O
peptide	O
gH625	O
has	O
been	O
previously	O
characterized	O
[	O
16	O
],	O
[	O
17	O
],	O
[	O
18	O
],	O
indicating	O
its	O
strong	O
interaction	O
with	O
LUVs	O
without	O
the	O
formation	O
of	O
pores	O
inside	O
the	O
bilayer	O
,	O
therefore	O
able	O
to	O
reduce	O
toxicity	O
problems	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
peptidodendrimer	O
is	O
more	O
effective	O
than	O
the	O
native	O
peptide	O
at	O
interacting	O
and	O
fusing	O
with	O
lipid	O
membranes	O
,	O
showing	O
its	O
efficacy	O
as	O
a	O
membrane	O
-	O
perturbing	O
agent	O
[	O
22	O
].	O

We	O
proposed	O
that	O
the	O
peptidodendrimer	O
translocates	O
across	O
the	O
bilayer	O
without	O
involving	O
essentially	O
the	O
endocytic	O
mechanism	O
.	O

The	O
mechanism	O
of	O
internalization	O
has	O
direct	O
implications	O
for	O
the	O
design	O
of	O
drug	O
delivery	O
,	O
cell	O
transfection	O
and	O
gene	O
therapy	O
agents	O
.	O

In	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
this	O
mechanism	O
for	O
the	O
peptide	O
functionalized	O
dendrimer	O
,	O
it	O
was	O
essential	O
to	O
investigate	O
possible	O
disruption	O
of	O
cell	O
membranes	O
.	O

Delivery	O
agents	O
that	O
have	O
the	O
ability	O
to	O
pass	O
through	O
membranes	O
without	O
causing	O
leakage	O
are	O
desirable	O
as	O
drug	O
delivery	O
vehicles	O
.	O

All	O
the	O
results	O
from	O
the	O
complementary	O
techniques	O
such	O
as	O
fluorescence	O
spectroscopy	O
,	O
surface	O
plasmon	O
resonance	O
and	O
isothermal	O
calorimetry	O
,	O
obtained	O
in	O
this	O
contribution	O
,	O
indicate	O
that	O
the	O
gH625	O
-	O
dendrimer	O
has	O
a	O
high	O
affinity	O
for	O
the	O
membrane	O
bilayer	O
;	O
moreover	O
,	O
we	O
were	O
able	O
to	O
determine	O
via	O
tryptophan	O
quenching	O
experiments	O
with	O
Br	O
-	O
PC	O
that	O
the	O
molecule	O
is	O
deeply	O
inserted	O
inside	O
the	O
bilayer	O
.	O

We	O
proved	O
that	O
the	O
molecule	O
is	O
able	O
to	O
cause	O
membrane	O
fusion	O
but	O
not	O
holes	O
in	O
the	O
bilayer	O
.	O

The	O
peptide	O
coupled	O
to	O
the	O
dendrimer	O
is	O
also	O
able	O
to	O
assume	O
a	O
helical	O
conformation	O
when	O
in	O
membrane	O
mimetic	O
environment	O
.	O

The	O
data	O
obtained	O
further	O
support	O
the	O
hypothesis	O
that	O
the	O
binding	O
to	O
the	O
membrane	O
bilayer	O
can	O
be	O
divided	O
at	O
least	O
into	O
two	O
steps	O
.	O

The	O
first	O
step	O
is	O
an	O
adsorption	O
process	O
that	O
leads	O
to	O
an	O
increased	O
macromolecule	O
concentration	O
on	O
the	O
membrane	O
.	O

The	O
second	O
step	O
is	O
a	O
hydrophobic	O
insertion	O
which	O
is	O
characterized	O
by	O
penetration	O
into	O
the	O
lipid	O
bilayer	O
and	O
probably	O
a	O
conformational	O
change	O
of	O
the	O
peptide	O
coupled	O
to	O
the	O
dendrimer	O
.	O

The	O
first	O
step	O
has	O
a	O
higher	O
binding	O
constant	O
compared	O
to	O
the	O
second	O
step	O
as	O
obtained	O
both	O
from	O
surface	O
plasmon	O
resonance	O
and	O
isothermal	O
calorimetry	O
.	O

These	O
data	O
further	O
support	O
the	O
view	O
that	O
the	O
mechanism	O
of	O
lipid	O
association	O
plays	O
a	O
key	O
role	O
in	O
the	O
translocation	O
activity	O
and	O
the	O
hypothesis	O
that	O
gH625	O
-	O
dendrimer	O
cellular	O
uptake	O
is	O
associated	O
with	O
its	O
ability	O
to	O
interact	O
with	O
membrane	O
lipids	O
and	O
to	O
temporarily	O
affect	O
membrane	O
organization	O
,	O
thereby	O
facilitating	O
insertion	O
into	O
the	O
membrane	O
and	O
translocation	O
.	O

The	O
translocating	O
ability	O
of	O
our	O
peptidodendrimer	O
is	O
different	O
from	O
the	O
most	O
commonly	O
used	O
cell	O
penetrating	O
peptides	O
(	O
such	O
as	O
the	O
HIV	B-DS
derived	O
TAT	O
peptide	O
)	O
and	O
from	O
the	O
mechanism	O
hypothesized	O
for	O
PAMAM	O
dendrimers	O
,	O
which	O
do	O
not	O
translocate	O
spontaneously	O
across	O
bilayers	O
but	O
rather	O
are	O
taken	O
up	O
by	O
cells	O
via	O
endocytosis	O
[	O
21	O
],	O
[	O
71	O
].	O

Our	O
peptido	O
-	O
dendrimer	O
presents	O
a	O
very	O
efficient	O
membrane	O
penetration	O
ability	O
and	O
our	O
findings	O
could	O
prove	O
helpful	O
for	O
a	O
better	O
understanding	O
of	O
the	O
advantages	O
of	O
combining	O
dendrimers	O
and	O
peptides	O
to	O
design	O
and	O
develop	O
new	O
and	O
effective	O
drug	O
delivery	O
tools	O
.	O

